###begin article-title 0
###xml 94 102 <span type="species:ncbi:9606">Patients</span>
Association of MICA-TM and MICB C1_2_A Microsatellite Polymorphisms with Tumor Progression in Patients with Colorectal Cancer
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 269 277 <span type="species:ncbi:9606">patients</span>
The major histocompatibility complex class I related A (MICA) and MICB molecules are ligands of NKG2D receptors on natural killer cells, gamma/delta T cells, and CD8ass T cells that mediate host antitumor immune response. The role of MICA-TM and MICB C1_2_A alleles in patients with colorectal cancer has not yet been investigated.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 539 540 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
We have analyzed the MICA-TM and MICB C1_2_A polymorphisms in colorectal cancer patients (n = 79) by polymerase chain reaction amplification, subsequent electrophoresis, and sequencing in comparison to a previously analyzed cohort of healthy controls (n = 306). Allele frequencies obtained for MICA-TM and MICB C1_2_A were compared to histopathological data regarding tumor invasion, disease progression, microsatellite instability, and the presence of KRAS mutations (codon 12) and analyzed for possible impact on tumor-related survival (n = 61).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 432 433 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 555 556 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 589 590 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 658 659 658 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
Allele frequencies of MICA-TM and MICB C1_2_A polymorphisms were not different in patients with colorectal cancer in comparison to normal controls. In colorectal cancer patients, MICA-TM A4 allele was directly and MICA-TM A5 allele was inversely associated with lymph node involvement and advanced UICC stages. Tumor-related survival in colorectal cancer patients was significantly reduced in the presence of the MICA-TM A4 allele (p = 0.015). In patients with microsatellite stable tumors, survival was reduced in association with the MICA-TM A4 allele (p = 0.006) and MICA-TM A9 allele (p = 0.034), but increased in patients showing the MICA-TM A5 allele (p = 0.042).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Specific MICA-TM alleles seem to influence tumor progression and midterm survival of patients with colorectal cancer, indicating an important role of host innate immune predisposition involving NKG2D mediated antitumor response.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 295 296 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 297 298 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 471 472 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 474 475 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 706 707 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 709 710 708 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 856 857 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 859 860 858 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1021 1022 1020 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1219 1221 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1683 1685 1682 1684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1686 1688 1685 1687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 941 949 <span type="species:ncbi:9606">patients</span>
###xml 1786 1794 <span type="species:ncbi:9606">patients</span>
###xml 2099 2107 <span type="species:ncbi:9606">patients</span>
The major histocompatibility complex class I chain related A (MICA) and MICB molecules are ligands of NKG2D receptors on natural killer (NK) cells, gamma/delta T cells, NKT cells, and CD8ass T cells, and mediate antitumor immune responses by stimulating innate and adaptive immune surveillance [1-3]. Several polymorphisms have been reported for MICA and MICB coding and noncoding sequences, located within the MHC class I region close to the tumor necrosis factor gene [4, 5]. The MICA-TM microsatellite polymorphism is present in exon 5 with eight alleles (A4, A5, A5.1, A6, A7, A8, A9, and A10), while the MICB gene contains a microsatellite polymorphism named C1_2_A in intron 1 comprising 16 alleles [6, 7]. Different MICA molecules were reported to vary in their affinities to soluble NKG2D receptors, which may influence antitumor immune responses [5, 8]. Recent studies have shown increased serum levels of soluble MICA molecules in patients with various malignancies with a correlation to advanced tumor stages [9]. Circulating tumor-derived soluble MICA molecules induce downregulation of NKG2D receptors on natural killer cells and thereby decrease responsiveness of tumor-antigen-specific effector T cells [10]. The mechanism of T and NK cell silencing by down regulation of NKGD cells induced by soluble ligands or chronic exposure to cell surface bound ligands may represent an important mechanism for tumor cells to escape host antitumor immune responses. Some reports have indicated associations of specific MICA alleles with epithelial tumors of the nasopharynx and gastric mucosa, with hematopoetic neoplasia and with chronic inflammatory and autoimmune disorders [11-15]. The allele and genotype frequencies of MICA-TM and MICB C1_2_A microsatellite polymorphisms in patients with colorectal cancer and a possible immunogenetic predisposition for the development of colorectal cancer or tumor progression have not yet been investigated. We have therefore analyzed the MICA-TM and MICB C1_2_A polymorphisms in samples of normal colon mucosa and tumor tissue from colorectal cancer patients in comparison to a cohort of healthy controls and investigated possible correlations to tumor characteristics and disease progression.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and Controls
###end title 13
###begin p 14
###xml 800 802 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 849 850 847 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 869 870 867 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 973 974 971 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 989 990 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1009 1010 1007 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1039 1040 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1354 1355 1352 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1364 1366 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
###xml 429 437 <span type="species:ncbi:9606">Patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
###xml 891 899 <span type="species:ncbi:9606">patients</span>
###xml 1278 1286 <span type="species:ncbi:9606">patients</span>
###xml 1427 1435 <span type="species:ncbi:9606">patients</span>
Seventy-nine patients with colorectal cancer were analyzed. The patients had been treated between Jan. 1998 and Dec. 2002 according to the principles of oncologic surgery, and tumors were classified according to TNM/UICC criteria following histopathological examination. Mean age was 67.4 +/- 10.9 years (range, 34-88 years), 52.5% of the patients were male and 47.5% female. Sixty-eight patients had sporadic colorectal cancer. Patients with evidence for polyposis cancer syndromes were excluded from the study. Eleven patients with clinical evidence for hereditary nonpolyposis colon cancer according to Bethesda criteria were analyzed separately for microsatellite instability to investigate a possible correlation of the DNA replication error pathway with alterations in host antitumor immunity [16]. Primary tumors were localized in the colon (n = 54) and rectum (n = 25). Twenty-three patients had UICC stage IV tumors with distant metastasis localized in the liver (n = 12), lungs (n = 6), peritoneum (n = 4), or at multiple sites (n = 4). Results of lymph node involvement (N-classification) were included in the study, when at least 12 lymph nodes were removed and histopathologically examined. Frequencies of MICA-TM and MICB C1_2_A polymorphisms in colorectal cancer patients were compared to a previously analyzed cohort of healthy controls (n = 306) [17]. The study was approved by the local ethics committee, and patients' informed consent was obtained.
###end p 14
###begin p 15
###xml 481 489 <span type="species:ncbi:9606">patients</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
Postoperative follow-up was performed according to the recommendations of the Munich cancer center and prospectively documented in an institutional data base. Follow-up intervals were initially every 6 months for 2 years, then yearly for up to the sixth year and at 2-year intervals for up to 10 years, including clinical examination, determination of carcinoembryonic antigen levels, upper abdomen sonography, abdominal CT scan, and total colonoscopy. Rectoscopy was performed in patients with rectal cancer or with an anastomosis below 12 cm as measured from the anocutanous line. Only patients with complete histopathological examination according to the TNM/UICC criteria and prospective follow-up were considered for analysis of survival times. Mean follow-up +/-SD was 56.2 +/- 36.3 months (range, 1-106 months).
###end p 15
###begin title 16
MICA-TM and MICB C1_2_A Genotyping
###end title 16
###begin p 17
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 362 364 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 260 267 <span type="species:ncbi:9606">persons</span>
MICA-TM and MICB C1_2_A polymorphisms were genotyped in genomic DNA isolated from normal colonic mucosa and colorectal tumor tissue, respectively [18]. Allele frequencies of MICA-TM and MICB C1_2_A polymorphisms were compared to a group of 306 healthy control persons, analyzed previously (mean age, 62.8 +/- 11.8 years; sampling period Jan. 1997 to Dec. 2000) [17]. The MICA-TM polymorphism was analyzed by polymerase chain reaction (PCR) amplification with the primers 5'-CAGAGTCATTGGCAGACA-3' (5'-Fam-labeled) and 5'-TTCTTCTTACAACAACGGAC-3'. The PCR products were separated by electrophoresis on denaturating 6% 0.3-mm polyacrylamide gels in the ALFexpress sequencer (Amersham Pharmacia, Uppsala, Sweden). The segregation of the MICA-TM alleles was controlled in 20 HLA-A, B, DR-typed families. Sequencing confirmed the allele size determined. As internal standards, a 73-bp PCR product from the transforming growth factor receptor II and ALFexpress Sizer 150 for MICB C1_2_A were used, respectively.
###end p 17
###begin p 18
###xml 458 460 458 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink">TM</sup>
MICB C1_2_A alleles of interest, including the gold standards, were sequenced either directly as PCR products or after subcloning into the vector pCR2.1 (Invitrogen). For sequence analysis of MICB C1_2_A microsatellite, alleles were amplified with the primers 5'-CCATAGTGTTTTCCATTGCAGGC-3' and 5'-AGCCATGAGAAGCTATGTGGGG-3'. The PCR products were purified using a QIA Quick PCR Purification Kit (Qiagen, Hilden, Germany) and were sequenced using the ABI PRISMTM dye terminator cycle sequencing kit on an ABI 373 DNA sequencer. The raw data were analyzed by the ABI Sequence Analysis program.
###end p 18
###begin title 19
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
Screening for Tumor Microsatellite Instability and KRAS Oncogene Mutations
###end title 19
###begin p 20
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR2</italic>
###xml 121 123 121 123 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10</sub>
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAX</italic>
###xml 131 132 131 132 <sub xmlns:xlink="http://www.w3.org/1999/xlink">8</sub>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MFD15</italic>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
Analysis of tumor microsatellite instability (MIN) was performed using the microsatellite markers BAT26, BAT40, TGFBR2(A)10, BAX(G)8, and the dinucleotide repeat MFD15 (D17S250), with modifications according to the meeting report of the National Cancer Institute Workshop on microsatellite instability [16]. Tumors exhibiting instability at 0-1 loci analyzed were considered as presenting low MIN and at >/=2 loci as high microsatellite instability (MIN-h).
###end p 20
###begin p 21
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 195 196 195 196 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 284 287 284 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bst</italic>
###xml 533 537 533 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
Tumor DNA was screened for KRAS mutations in codon 12 (glycine, GGT) by primer-mediated restriction fragment length polymorphism (RFLP) analysis. The primers used were ACTGAATATAAACTTGTGGTAGTTGGACCT and TCATGAAAATGGTCAGAGAA, the underlined base within the forward primer introduces a BstN I restriction site in the amplified wild-type sequence. The colon carcinoma cell line SW480 carrying a homozygous Val mutation at codon 12 was used as a positive control for RFLP analysis. Additionally, all tumor DNA samples displaying mutated KRAS sequences at codon 12 in RFLP analysis were further analyzed by sequencing in order to confirm to results of RFLP analysis and to determine which mutation was present. For sequence analysis, a 288-bp amplificate was generated using the primers ACTGGTGGAGTATTTGATAG and ACTCATGAAAATGGTCAGAG.
###end p 21
###begin title 22
Statistical Analysis
###end title 22
###begin p 23
###xml 820 821 820 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Haplotype gene frequencies were determined by gene counting assuming homozygosity, if at a given locus only one allele could be identified. Correlations to histopathological parameters were performed comparing MICA-TM and MICB C1_2_A alleles with tumor invasion, lymph node involvement, presence of distant metastasis, and UICC stages. Statistical significance for the two-point associations was tested by Chi-square calculation in the 2 x 2 table and Pearson's coefficient, Fisher's exact test (two-sided) or phi coefficient was used, when appropriate. Survival times were calculated by Kaplan-Meier curves, and the log rank test was used for statistical analysis and comparison of different variables. For multivariate analysis, Cox regression analysis was performed using the Wald test for comparison of variables. A p value of less than 0.05 was used to indicate statistical significance. Statistical analysis was performed using the SPSS statistical software (SPSS version 11.5).
###end p 23
###begin title 24
Results
###end title 24
###begin title 25
MICA-TM and MICB C1_2_A Allele Frequencies
###end title 25
###begin p 26
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">I</xref>
###xml 255 256 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 323 324 323 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 566 573 566 573 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table I</label>
###xml 573 691 573 691 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Allele Frequencies (in %) of Microsatellites MICA-TM and MICB C1_2_A in Colorectal Cancer Patients and Control Persons</p>
###xml 573 691 573 691 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">Allele Frequencies (in %) of Microsatellites MICA-TM and MICB C1_2_A in Colorectal Cancer Patients and Control Persons</p></caption>
###xml 691 692 691 692 <th xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</th>
###xml 720 721 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 692 727 692 727 <th xmlns:xlink="http://www.w3.org/1999/xlink">Colorectal cancer patients (<italic>n</italic>&#8201;=&#8201;79)</th>
###xml 737 738 737 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 727 745 727 745 <th xmlns:xlink="http://www.w3.org/1999/xlink">Controls (<italic>n</italic>&#8201;=&#8201;306)</th>
###xml 691 745 691 745 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>&#160;</th><th>Colorectal cancer patients (<italic>n</italic>&#8201;=&#8201;79)</th><th>Controls (<italic>n</italic>&#8201;=&#8201;306)</th></tr>
###xml 691 745 691 745 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>&#160;</th><th>Colorectal cancer patients (<italic>n</italic>&#8201;=&#8201;79)</th><th>Controls (<italic>n</italic>&#8201;=&#8201;306)</th></tr></thead>
###xml 745 759 745 759 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">MICA-TM allele</td>
###xml 745 759 745 759 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="3">MICA-TM allele</td></tr>
###xml 759 762 759 762 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A4</td>
###xml 762 766 762 766 <td xmlns:xlink="http://www.w3.org/1999/xlink">11.9</td>
###xml 766 770 766 770 <td xmlns:xlink="http://www.w3.org/1999/xlink">11.7</td>
###xml 759 770 759 770 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A4</td><td>11.9</td><td>11.7</td></tr>
###xml 770 773 770 773 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A5</td>
###xml 773 777 773 777 <td xmlns:xlink="http://www.w3.org/1999/xlink">10.6</td>
###xml 777 781 777 781 <td xmlns:xlink="http://www.w3.org/1999/xlink">13.6</td>
###xml 770 781 770 781 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A5</td><td>10.6</td><td>13.6</td></tr>
###xml 781 786 781 786 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A5.1</td>
###xml 786 790 786 790 <td xmlns:xlink="http://www.w3.org/1999/xlink">43.1</td>
###xml 790 794 790 794 <td xmlns:xlink="http://www.w3.org/1999/xlink">37.0</td>
###xml 781 794 781 794 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A5.1</td><td>43.1</td><td>37.0</td></tr>
###xml 794 797 794 797 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A6</td>
###xml 797 801 797 801 <td xmlns:xlink="http://www.w3.org/1999/xlink">21.9</td>
###xml 801 805 801 805 <td xmlns:xlink="http://www.w3.org/1999/xlink">22.4</td>
###xml 794 805 794 805 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A6</td><td>21.9</td><td>22.4</td></tr>
###xml 805 808 805 808 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A9</td>
###xml 808 812 808 812 <td xmlns:xlink="http://www.w3.org/1999/xlink">12.5</td>
###xml 812 816 812 816 <td xmlns:xlink="http://www.w3.org/1999/xlink">15.3</td>
###xml 805 816 805 816 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A9</td><td>12.5</td><td>15.3</td></tr>
###xml 816 834 816 834 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">MICB C1_2_A allele</td>
###xml 816 834 816 834 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="3">MICB C1_2_A allele</td></tr>
###xml 834 839 834 839 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA14</td>
###xml 839 843 839 843 <td xmlns:xlink="http://www.w3.org/1999/xlink">16.6</td>
###xml 843 847 843 847 <td xmlns:xlink="http://www.w3.org/1999/xlink">18.5</td>
###xml 834 847 834 847 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA14</td><td>16.6</td><td>18.5</td></tr>
###xml 847 852 847 852 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA15</td>
###xml 852 856 852 856 <td xmlns:xlink="http://www.w3.org/1999/xlink">19.2</td>
###xml 856 860 856 860 <td xmlns:xlink="http://www.w3.org/1999/xlink">10.5</td>
###xml 847 860 847 860 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA15</td><td>19.2</td><td>10.5</td></tr>
###xml 860 865 860 865 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA16</td>
###xml 865 869 865 869 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 869 872 869 872 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.2</td>
###xml 860 872 860 872 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA16</td><td>n.d.</td><td>0.2</td></tr>
###xml 872 877 872 877 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA17</td>
###xml 877 881 877 881 <td xmlns:xlink="http://www.w3.org/1999/xlink">11.4</td>
###xml 881 885 881 885 <td xmlns:xlink="http://www.w3.org/1999/xlink">20.3</td>
###xml 872 885 872 885 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA17</td><td>11.4</td><td>20.3</td></tr>
###xml 885 890 885 890 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA18</td>
###xml 890 893 890 893 <td xmlns:xlink="http://www.w3.org/1999/xlink">8.3</td>
###xml 893 896 893 896 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.2</td>
###xml 885 896 885 896 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA18</td><td>8.3</td><td>7.2</td></tr>
###xml 896 901 896 901 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA19</td>
###xml 901 905 901 905 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.1.</td>
###xml 905 908 905 908 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.1</td>
###xml 896 908 896 908 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA19</td><td>3.1.</td><td>1.1</td></tr>
###xml 908 913 908 913 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA20</td>
###xml 913 916 913 916 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.7</td>
###xml 916 919 916 919 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.1</td>
###xml 908 919 908 919 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA20</td><td>3.7</td><td>4.1</td></tr>
###xml 919 924 919 924 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA21</td>
###xml 924 927 924 927 <td xmlns:xlink="http://www.w3.org/1999/xlink">8.0</td>
###xml 927 930 927 930 <td xmlns:xlink="http://www.w3.org/1999/xlink">8.9</td>
###xml 919 930 919 930 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA21</td><td>8.0</td><td>8.9</td></tr>
###xml 930 935 930 935 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA22</td>
###xml 935 938 935 938 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.3</td>
###xml 938 941 938 941 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.2</td>
###xml 930 941 930 941 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA22</td><td>4.3</td><td>7.2</td></tr>
###xml 941 946 941 946 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA23</td>
###xml 946 949 946 949 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.6</td>
###xml 949 952 949 952 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.9</td>
###xml 941 952 941 952 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA23</td><td>5.6</td><td>5.9</td></tr>
###xml 952 957 952 957 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA24</td>
###xml 957 961 957 961 <td xmlns:xlink="http://www.w3.org/1999/xlink">14.8</td>
###xml 961 965 961 965 <td xmlns:xlink="http://www.w3.org/1999/xlink">10.9</td>
###xml 952 965 952 965 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA24</td><td>14.8</td><td>10.9</td></tr>
###xml 965 970 965 970 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA25</td>
###xml 970 973 970 973 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.8</td>
###xml 973 976 973 976 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.9</td>
###xml 965 976 965 976 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA25</td><td>4.8</td><td>3.9</td></tr>
###xml 976 981 976 981 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA26</td>
###xml 981 985 981 985 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 985 988 985 988 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.8</td>
###xml 976 988 976 988 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA26</td><td>n.d.</td><td>0.8</td></tr>
###xml 988 993 988 993 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA27</td>
###xml 993 997 993 997 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 997 1000 997 1000 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.5</td>
###xml 988 1000 988 1000 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA27</td><td>n.d.</td><td>0.5</td></tr>
###xml 745 1000 745 1000 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="3">MICA-TM allele</td></tr><tr><td>&#160;A4</td><td>11.9</td><td>11.7</td></tr><tr><td>&#160;A5</td><td>10.6</td><td>13.6</td></tr><tr><td>&#160;A5.1</td><td>43.1</td><td>37.0</td></tr><tr><td>&#160;A6</td><td>21.9</td><td>22.4</td></tr><tr><td>&#160;A9</td><td>12.5</td><td>15.3</td></tr><tr><td colspan="3">MICB C1_2_A allele</td></tr><tr><td>&#160;CA14</td><td>16.6</td><td>18.5</td></tr><tr><td>&#160;CA15</td><td>19.2</td><td>10.5</td></tr><tr><td>&#160;CA16</td><td>n.d.</td><td>0.2</td></tr><tr><td>&#160;CA17</td><td>11.4</td><td>20.3</td></tr><tr><td>&#160;CA18</td><td>8.3</td><td>7.2</td></tr><tr><td>&#160;CA19</td><td>3.1.</td><td>1.1</td></tr><tr><td>&#160;CA20</td><td>3.7</td><td>4.1</td></tr><tr><td>&#160;CA21</td><td>8.0</td><td>8.9</td></tr><tr><td>&#160;CA22</td><td>4.3</td><td>7.2</td></tr><tr><td>&#160;CA23</td><td>5.6</td><td>5.9</td></tr><tr><td>&#160;CA24</td><td>14.8</td><td>10.9</td></tr><tr><td>&#160;CA25</td><td>4.8</td><td>3.9</td></tr><tr><td>&#160;CA26</td><td>n.d.</td><td>0.8</td></tr><tr><td>&#160;CA27</td><td>n.d.</td><td>0.5</td></tr></tbody>
###xml 691 1000 691 1000 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th>Colorectal cancer patients (<italic>n</italic>&#8201;=&#8201;79)</th><th>Controls (<italic>n</italic>&#8201;=&#8201;306)</th></tr></thead><tbody><tr><td colspan="3">MICA-TM allele</td></tr><tr><td>&#160;A4</td><td>11.9</td><td>11.7</td></tr><tr><td>&#160;A5</td><td>10.6</td><td>13.6</td></tr><tr><td>&#160;A5.1</td><td>43.1</td><td>37.0</td></tr><tr><td>&#160;A6</td><td>21.9</td><td>22.4</td></tr><tr><td>&#160;A9</td><td>12.5</td><td>15.3</td></tr><tr><td colspan="3">MICB C1_2_A allele</td></tr><tr><td>&#160;CA14</td><td>16.6</td><td>18.5</td></tr><tr><td>&#160;CA15</td><td>19.2</td><td>10.5</td></tr><tr><td>&#160;CA16</td><td>n.d.</td><td>0.2</td></tr><tr><td>&#160;CA17</td><td>11.4</td><td>20.3</td></tr><tr><td>&#160;CA18</td><td>8.3</td><td>7.2</td></tr><tr><td>&#160;CA19</td><td>3.1.</td><td>1.1</td></tr><tr><td>&#160;CA20</td><td>3.7</td><td>4.1</td></tr><tr><td>&#160;CA21</td><td>8.0</td><td>8.9</td></tr><tr><td>&#160;CA22</td><td>4.3</td><td>7.2</td></tr><tr><td>&#160;CA23</td><td>5.6</td><td>5.9</td></tr><tr><td>&#160;CA24</td><td>14.8</td><td>10.9</td></tr><tr><td>&#160;CA25</td><td>4.8</td><td>3.9</td></tr><tr><td>&#160;CA26</td><td>n.d.</td><td>0.8</td></tr><tr><td>&#160;CA27</td><td>n.d.</td><td>0.5</td></tr></tbody></table>
###xml 1056 1058 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1000 1059 1000 1059 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Allele frequencies of control persons were reported in [<xref ref-type="bibr" rid="CR18">18</xref>]</p>
###xml 1059 1063 1059 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</italic>
###xml 1059 1100 1059 1100 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><italic>n.d.</italic> not detected in our patients' cohort</p>
###xml 1000 1100 1000 1100 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Allele frequencies of control persons were reported in [<xref ref-type="bibr" rid="CR18">18</xref>]</p><p textid="29"><italic>n.d.</italic> not detected in our patients' cohort</p></table-wrap-foot>
###xml 566 1100 566 1100 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table I</label><caption><p textid="27">Allele Frequencies (in %) of Microsatellites MICA-TM and MICB C1_2_A in Colorectal Cancer Patients and Control Persons</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th>Colorectal cancer patients (<italic>n</italic>&#8201;=&#8201;79)</th><th>Controls (<italic>n</italic>&#8201;=&#8201;306)</th></tr></thead><tbody><tr><td colspan="3">MICA-TM allele</td></tr><tr><td>&#160;A4</td><td>11.9</td><td>11.7</td></tr><tr><td>&#160;A5</td><td>10.6</td><td>13.6</td></tr><tr><td>&#160;A5.1</td><td>43.1</td><td>37.0</td></tr><tr><td>&#160;A6</td><td>21.9</td><td>22.4</td></tr><tr><td>&#160;A9</td><td>12.5</td><td>15.3</td></tr><tr><td colspan="3">MICB C1_2_A allele</td></tr><tr><td>&#160;CA14</td><td>16.6</td><td>18.5</td></tr><tr><td>&#160;CA15</td><td>19.2</td><td>10.5</td></tr><tr><td>&#160;CA16</td><td>n.d.</td><td>0.2</td></tr><tr><td>&#160;CA17</td><td>11.4</td><td>20.3</td></tr><tr><td>&#160;CA18</td><td>8.3</td><td>7.2</td></tr><tr><td>&#160;CA19</td><td>3.1.</td><td>1.1</td></tr><tr><td>&#160;CA20</td><td>3.7</td><td>4.1</td></tr><tr><td>&#160;CA21</td><td>8.0</td><td>8.9</td></tr><tr><td>&#160;CA22</td><td>4.3</td><td>7.2</td></tr><tr><td>&#160;CA23</td><td>5.6</td><td>5.9</td></tr><tr><td>&#160;CA24</td><td>14.8</td><td>10.9</td></tr><tr><td>&#160;CA25</td><td>4.8</td><td>3.9</td></tr><tr><td>&#160;CA26</td><td>n.d.</td><td>0.8</td></tr><tr><td>&#160;CA27</td><td>n.d.</td><td>0.5</td></tr></tbody></table><table-wrap-foot><p textid="28">Allele frequencies of control persons were reported in [<xref ref-type="bibr" rid="CR18">18</xref>]</p><p textid="29"><italic>n.d.</italic> not detected in our patients' cohort</p></table-wrap-foot></table-wrap>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 663 671 <span type="species:ncbi:9606">Patients</span>
###xml 684 691 <span type="species:ncbi:9606">Persons</span>
###xml 710 718 <span type="species:ncbi:9606">patients</span>
###xml 1030 1037 <span type="species:ncbi:9606">persons</span>
###xml 1084 1092 <span type="species:ncbi:9606">patients</span>
Allele frequencies of MICA-TM and MICB C1_2_A in colorectal cancer patients did not differ compared to a cohort of healthy control individuals (Table I). Homozygosity was most frequently observed in colorectal cancer patients for the MICA-TM A5.1 allele (n = 13; 16.4% of all patients) and for the MICB C1_2_A CA15 allele (n = 4; 5.1% of all patients). Nonsignificant trends were observed in our cohort regarding an increased MICB C1_2_A CA15 allele frequency (19.2% vs 10.5%) and a reduced CA17 allele frequency (11.4% vs 20.3%) in comparison to the control group. Table IAllele Frequencies (in %) of Microsatellites MICA-TM and MICB C1_2_A in Colorectal Cancer Patients and Control Persons Colorectal cancer patients (n = 79)Controls (n = 306)MICA-TM allele A411.911.7 A510.613.6 A5.143.137.0 A621.922.4 A912.515.3MICB C1_2_A allele CA1416.618.5 CA1519.210.5 CA16n.d.0.2 CA1711.420.3 CA188.37.2 CA193.1.1.1 CA203.74.1 CA218.08.9 CA224.37.2 CA235.65.9 CA2414.810.9 CA254.83.9 CA26n.d.0.8 CA27n.d.0.5Allele frequencies of control persons were reported in [18]n.d. not detected in our patients' cohort
###end p 26
###begin p 27
###xml 90 98 <span type="species:ncbi:9606">Patients</span>
###xml 111 118 <span type="species:ncbi:9606">Persons</span>
Allele Frequencies (in %) of Microsatellites MICA-TM and MICB C1_2_A in Colorectal Cancer Patients and Control Persons
###end p 27
###begin p 28
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 30 37 <span type="species:ncbi:9606">persons</span>
Allele frequencies of control persons were reported in [18]
###end p 28
###begin p 29
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</italic>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
n.d. not detected in our patients' cohort
###end p 29
###begin title 30
Association of MICA-TM and MICB C1_2_A Alleles with Tumor-Associated Variables
###end title 30
###begin p 31
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">II</xref>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 488 489 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 532 533 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 570 571 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 700 701 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 761 762 761 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 773 781 773 781 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table II</label>
###xml 781 874 781 874 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">Comparison of MICA-TM Allele Frequencies with Tumor-Associated Clinicopathological Parameters</p>
###xml 781 874 781 874 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">Comparison of MICA-TM Allele Frequencies with Tumor-Associated Clinicopathological Parameters</p></caption>
###xml 874 894 874 894 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Tumor classification</th>
###xml 894 908 894 908 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">MICA-TM allele</th>
###xml 874 908 874 908 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Tumor classification</th><th colspan="5">MICA-TM allele</th></tr>
###xml 908 910 908 910 <th xmlns:xlink="http://www.w3.org/1999/xlink">A4</th>
###xml 910 912 910 912 <th xmlns:xlink="http://www.w3.org/1999/xlink">A5</th>
###xml 912 916 912 916 <th xmlns:xlink="http://www.w3.org/1999/xlink">A5.1</th>
###xml 916 918 916 918 <th xmlns:xlink="http://www.w3.org/1999/xlink">A6</th>
###xml 918 920 918 920 <th xmlns:xlink="http://www.w3.org/1999/xlink">A9</th>
###xml 908 920 908 920 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>A4</th><th>A5</th><th>A5.1</th><th>A6</th><th>A9</th></tr>
###xml 874 920 874 920 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Tumor classification</th><th colspan="5">MICA-TM allele</th></tr><tr><th>A4</th><th>A5</th><th>A5.1</th><th>A6</th><th>A9</th></tr></thead>
###xml 920 934 920 934 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">Tumor invasion</td>
###xml 920 934 920 934 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">Tumor invasion</td></tr>
###xml 934 939 934 939 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;T1/2</td>
###xml 939 943 939 943 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/17</td>
###xml 943 947 943 947 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/17</td>
###xml 947 952 947 952 <td xmlns:xlink="http://www.w3.org/1999/xlink">12/17</td>
###xml 952 956 952 956 <td xmlns:xlink="http://www.w3.org/1999/xlink">7/17</td>
###xml 956 960 956 960 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/17</td>
###xml 934 960 934 960 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;T1/2</td><td>3/17</td><td>3/17</td><td>12/17</td><td>7/17</td><td>3/17</td></tr>
###xml 960 965 960 965 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;T3/4</td>
###xml 965 970 965 970 <td xmlns:xlink="http://www.w3.org/1999/xlink">11/44</td>
###xml 970 974 970 974 <td xmlns:xlink="http://www.w3.org/1999/xlink">8/44</td>
###xml 974 979 974 979 <td xmlns:xlink="http://www.w3.org/1999/xlink">32/44</td>
###xml 979 984 979 984 <td xmlns:xlink="http://www.w3.org/1999/xlink">18/44</td>
###xml 984 989 984 989 <td xmlns:xlink="http://www.w3.org/1999/xlink">11/44</td>
###xml 960 989 960 989 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;T3/4</td><td>11/44</td><td>8/44</td><td>32/44</td><td>18/44</td><td>11/44</td></tr>
###xml 989 1011 989 1011 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">Lymph node involvement</td>
###xml 989 1011 989 1011 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">Lymph node involvement</td></tr>
###xml 1011 1014 1011 1014 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;N0</td>
###xml 1014 1018 1014 1018 <td xmlns:xlink="http://www.w3.org/1999/xlink">9/51</td>
###xml 1018 1023 1018 1023 <td xmlns:xlink="http://www.w3.org/1999/xlink">11/51</td>
###xml 1023 1028 1023 1028 <td xmlns:xlink="http://www.w3.org/1999/xlink">39/51</td>
###xml 1028 1033 1028 1033 <td xmlns:xlink="http://www.w3.org/1999/xlink">20/51</td>
###xml 1033 1038 1033 1038 <td xmlns:xlink="http://www.w3.org/1999/xlink">11/51</td>
###xml 1011 1038 1011 1038 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;N0</td><td>9/51</td><td>11/51</td><td>39/51</td><td>20/51</td><td>11/51</td></tr>
###xml 1038 1043 1038 1043 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;N1-3</td>
###xml 1043 1047 1043 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink">5/10</td>
###xml 1051 1052 1051 1052 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1047 1052 1047 1052 <td xmlns:xlink="http://www.w3.org/1999/xlink">0/10<sup>a</sup></td>
###xml 1052 1056 1052 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink">6/10</td>
###xml 1056 1060 1056 1060 <td xmlns:xlink="http://www.w3.org/1999/xlink">5/10</td>
###xml 1060 1064 1060 1064 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/10</td>
###xml 1038 1064 1038 1064 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;N1-3</td><td>5/10</td><td>0/10<sup>a</sup></td><td>6/10</td><td>5/10</td><td>3/10</td></tr>
###xml 1064 1082 1064 1082 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">Distant metastasis</td>
###xml 1064 1082 1064 1082 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">Distant metastasis</td></tr>
###xml 1082 1085 1082 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;M0</td>
###xml 1085 1089 1085 1089 <td xmlns:xlink="http://www.w3.org/1999/xlink">8/47</td>
###xml 1089 1094 1089 1094 <td xmlns:xlink="http://www.w3.org/1999/xlink">12/47</td>
###xml 1094 1099 1094 1099 <td xmlns:xlink="http://www.w3.org/1999/xlink">35/47</td>
###xml 1099 1104 1099 1104 <td xmlns:xlink="http://www.w3.org/1999/xlink">17/47</td>
###xml 1104 1109 1104 1109 <td xmlns:xlink="http://www.w3.org/1999/xlink">11/47</td>
###xml 1082 1109 1082 1109 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;M0</td><td>8/47</td><td>12/47</td><td>35/47</td><td>17/47</td><td>11/47</td></tr>
###xml 1109 1112 1109 1112 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;M1</td>
###xml 1117 1118 1117 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1112 1118 1112 1118 <td xmlns:xlink="http://www.w3.org/1999/xlink">10/23<sup>b</sup></td>
###xml 1122 1123 1122 1123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1118 1123 1118 1123 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/23<sup>c</sup></td>
###xml 1123 1128 1123 1128 <td xmlns:xlink="http://www.w3.org/1999/xlink">14/23</td>
###xml 1128 1133 1128 1133 <td xmlns:xlink="http://www.w3.org/1999/xlink">11/23</td>
###xml 1133 1137 1133 1137 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/23</td>
###xml 1109 1137 1109 1137 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;M1</td><td>10/23<sup>b</sup></td><td>1/23<sup>c</sup></td><td>14/23</td><td>11/23</td><td>3/23</td></tr>
###xml 1137 1148 1137 1148 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">UICC stages</td>
###xml 1137 1148 1137 1148 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">UICC stages</td></tr>
###xml 1148 1158 1148 1158 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;UICC I/II</td>
###xml 1158 1162 1158 1162 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/30</td>
###xml 1162 1167 1162 1167 <td xmlns:xlink="http://www.w3.org/1999/xlink">10/30</td>
###xml 1167 1172 1167 1172 <td xmlns:xlink="http://www.w3.org/1999/xlink">22/30</td>
###xml 1172 1177 1172 1177 <td xmlns:xlink="http://www.w3.org/1999/xlink">11/30</td>
###xml 1177 1181 1177 1181 <td xmlns:xlink="http://www.w3.org/1999/xlink">5/30</td>
###xml 1148 1181 1148 1181 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;UICC I/II</td><td>4/30</td><td>10/30</td><td>22/30</td><td>11/30</td><td>5/30</td></tr>
###xml 1181 1193 1181 1193 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;UICC III/IV</td>
###xml 1193 1198 1193 1198 <td xmlns:xlink="http://www.w3.org/1999/xlink">14/39</td>
###xml 1202 1203 1202 1203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 1198 1203 1198 1203 <td xmlns:xlink="http://www.w3.org/1999/xlink">2/39<sup>d</sup></td>
###xml 1203 1208 1203 1208 <td xmlns:xlink="http://www.w3.org/1999/xlink">26/39</td>
###xml 1208 1213 1208 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink">17/39</td>
###xml 1213 1217 1213 1217 <td xmlns:xlink="http://www.w3.org/1999/xlink">9/39</td>
###xml 1181 1217 1181 1217 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;UICC III/IV</td><td>14/39</td><td>2/39<sup>d</sup></td><td>26/39</td><td>17/39</td><td>9/39</td></tr>
###xml 920 1217 920 1217 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="6">Tumor invasion</td></tr><tr><td>&#160;T1/2</td><td>3/17</td><td>3/17</td><td>12/17</td><td>7/17</td><td>3/17</td></tr><tr><td>&#160;T3/4</td><td>11/44</td><td>8/44</td><td>32/44</td><td>18/44</td><td>11/44</td></tr><tr><td colspan="6">Lymph node involvement</td></tr><tr><td>&#160;N0</td><td>9/51</td><td>11/51</td><td>39/51</td><td>20/51</td><td>11/51</td></tr><tr><td>&#160;N1-3</td><td>5/10</td><td>0/10<sup>a</sup></td><td>6/10</td><td>5/10</td><td>3/10</td></tr><tr><td colspan="6">Distant metastasis</td></tr><tr><td>&#160;M0</td><td>8/47</td><td>12/47</td><td>35/47</td><td>17/47</td><td>11/47</td></tr><tr><td>&#160;M1</td><td>10/23<sup>b</sup></td><td>1/23<sup>c</sup></td><td>14/23</td><td>11/23</td><td>3/23</td></tr><tr><td colspan="6">UICC stages</td></tr><tr><td>&#160;UICC I/II</td><td>4/30</td><td>10/30</td><td>22/30</td><td>11/30</td><td>5/30</td></tr><tr><td>&#160;UICC III/IV</td><td>14/39</td><td>2/39<sup>d</sup></td><td>26/39</td><td>17/39</td><td>9/39</td></tr></tbody>
###xml 874 1217 874 1217 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Tumor classification</th><th colspan="5">MICA-TM allele</th></tr><tr><th>A4</th><th>A5</th><th>A5.1</th><th>A6</th><th>A9</th></tr></thead><tbody><tr><td colspan="6">Tumor invasion</td></tr><tr><td>&#160;T1/2</td><td>3/17</td><td>3/17</td><td>12/17</td><td>7/17</td><td>3/17</td></tr><tr><td>&#160;T3/4</td><td>11/44</td><td>8/44</td><td>32/44</td><td>18/44</td><td>11/44</td></tr><tr><td colspan="6">Lymph node involvement</td></tr><tr><td>&#160;N0</td><td>9/51</td><td>11/51</td><td>39/51</td><td>20/51</td><td>11/51</td></tr><tr><td>&#160;N1-3</td><td>5/10</td><td>0/10<sup>a</sup></td><td>6/10</td><td>5/10</td><td>3/10</td></tr><tr><td colspan="6">Distant metastasis</td></tr><tr><td>&#160;M0</td><td>8/47</td><td>12/47</td><td>35/47</td><td>17/47</td><td>11/47</td></tr><tr><td>&#160;M1</td><td>10/23<sup>b</sup></td><td>1/23<sup>c</sup></td><td>14/23</td><td>11/23</td><td>3/23</td></tr><tr><td colspan="6">UICC stages</td></tr><tr><td>&#160;UICC I/II</td><td>4/30</td><td>10/30</td><td>22/30</td><td>11/30</td><td>5/30</td></tr><tr><td>&#160;UICC III/IV</td><td>14/39</td><td>2/39<sup>d</sup></td><td>26/39</td><td>17/39</td><td>9/39</td></tr></tbody></table>
###xml 1217 1218 1217 1218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1218 1219 1218 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1217 1226 1217 1226 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><sup>a</sup><italic>p</italic>&#8201;&lt;&#8201;0.05</p>
###xml 1226 1227 1226 1227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1227 1228 1227 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1226 1236 1226 1236 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34"><sup>b</sup><italic>p</italic>&#8201;&lt;&#8201;0.023</p>
###xml 1236 1237 1236 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1237 1238 1237 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1236 1246 1236 1246 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><sup>c</sup><italic>p</italic>&#8201;&lt;&#8201;0.048</p>
###xml 1246 1247 1246 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 1247 1248 1247 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1246 1255 1246 1255 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><sup>d</sup><italic>p</italic>&#8201;&lt;&#8201;0.02</p>
###xml 1217 1255 1217 1255 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33"><sup>a</sup><italic>p</italic>&#8201;&lt;&#8201;0.05</p><p textid="34"><sup>b</sup><italic>p</italic>&#8201;&lt;&#8201;0.023</p><p textid="35"><sup>c</sup><italic>p</italic>&#8201;&lt;&#8201;0.048</p><p textid="36"><sup>d</sup><italic>p</italic>&#8201;&lt;&#8201;0.02</p></table-wrap-foot>
###xml 773 1255 773 1255 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table II</label><caption><p textid="32">Comparison of MICA-TM Allele Frequencies with Tumor-Associated Clinicopathological Parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Tumor classification</th><th colspan="5">MICA-TM allele</th></tr><tr><th>A4</th><th>A5</th><th>A5.1</th><th>A6</th><th>A9</th></tr></thead><tbody><tr><td colspan="6">Tumor invasion</td></tr><tr><td>&#160;T1/2</td><td>3/17</td><td>3/17</td><td>12/17</td><td>7/17</td><td>3/17</td></tr><tr><td>&#160;T3/4</td><td>11/44</td><td>8/44</td><td>32/44</td><td>18/44</td><td>11/44</td></tr><tr><td colspan="6">Lymph node involvement</td></tr><tr><td>&#160;N0</td><td>9/51</td><td>11/51</td><td>39/51</td><td>20/51</td><td>11/51</td></tr><tr><td>&#160;N1-3</td><td>5/10</td><td>0/10<sup>a</sup></td><td>6/10</td><td>5/10</td><td>3/10</td></tr><tr><td colspan="6">Distant metastasis</td></tr><tr><td>&#160;M0</td><td>8/47</td><td>12/47</td><td>35/47</td><td>17/47</td><td>11/47</td></tr><tr><td>&#160;M1</td><td>10/23<sup>b</sup></td><td>1/23<sup>c</sup></td><td>14/23</td><td>11/23</td><td>3/23</td></tr><tr><td colspan="6">UICC stages</td></tr><tr><td>&#160;UICC I/II</td><td>4/30</td><td>10/30</td><td>22/30</td><td>11/30</td><td>5/30</td></tr><tr><td>&#160;UICC III/IV</td><td>14/39</td><td>2/39<sup>d</sup></td><td>26/39</td><td>17/39</td><td>9/39</td></tr></tbody></table><table-wrap-foot><p textid="33"><sup>a</sup><italic>p</italic>&#8201;&lt;&#8201;0.05</p><p textid="34"><sup>b</sup><italic>p</italic>&#8201;&lt;&#8201;0.023</p><p textid="35"><sup>c</sup><italic>p</italic>&#8201;&lt;&#8201;0.048</p><p textid="36"><sup>d</sup><italic>p</italic>&#8201;&lt;&#8201;0.02</p></table-wrap-foot></table-wrap>
MICA-TM and MICB C1_2_A alleles were investigated for possible correlation to various tumor-associated variables, including tumor invasion, lymph node involvement, presence of distant metastasis, UICC stages, microsatellite instability, and detection of KRAS mutations (codon 12). As shown in Table II, the MICA-TM A4 allele was associated with the presence of distant metastasis (p = 0.023). The presence of the MICA-TM A5 allele showed an inverse association to lymph node involvement (p = 0.015), presence of distant metastasis (p = 0.048), and advanced UICC stages (p = 0.003). The analysis of MICB C1_2_A alleles showed an association of the CA14 allele with the presence of distant metastasis (p = 0.045) and of the CA21 allele with advanced UICC stages (p = 0.047). Table IIComparison of MICA-TM Allele Frequencies with Tumor-Associated Clinicopathological ParametersTumor classificationMICA-TM alleleA4A5A5.1A6A9Tumor invasion T1/23/173/1712/177/173/17 T3/411/448/4432/4418/4411/44Lymph node involvement N09/5111/5139/5120/5111/51 N1-35/100/10a6/105/103/10Distant metastasis M08/4712/4735/4717/4711/47 M110/23b1/23c14/2311/233/23UICC stages UICC I/II4/3010/3022/3011/305/30 UICC III/IV14/392/39d26/3917/399/39ap < 0.05bp < 0.023cp < 0.048dp < 0.02
###end p 31
###begin p 32
Comparison of MICA-TM Allele Frequencies with Tumor-Associated Clinicopathological Parameters
###end p 32
###begin p 33
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
ap < 0.05
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
bp < 0.023
###end p 34
###begin p 35
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
cp < 0.048
###end p 35
###begin p 36
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
dp < 0.02
###end p 36
###begin title 37
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
MICA-TM and MICB C1_2_A Allele Distribution, Microsatellite Instability, and KRAS Mutations
###end title 37
###begin p 38
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 245 248 245 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">III</xref>
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 341 345 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 477 478 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 489 490 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 502 503 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 515 516 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 729 733 729 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 779 780 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 791 800 791 800 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table III</label>
###xml 917 921 917 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 800 940 800 940 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">MICA-TM and MICB C1_2_A Polymorphisms in Colorectal Cancer Patients with Regard to Tumor Microsatellite Stability or <italic>KRAS</italic> Codon 12 Mutations</p>
###xml 800 940 800 940 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">MICA-TM and MICB C1_2_A Polymorphisms in Colorectal Cancer Patients with Regard to Tumor Microsatellite Stability or <italic>KRAS</italic> Codon 12 Mutations</p></caption>
###xml 940 959 940 959 <th xmlns:xlink="http://www.w3.org/1999/xlink">MICA-TM/MICB C1_2_A</th>
###xml 959 983 959 983 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">Tumor-related parameters</th>
###xml 940 983 940 983 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>MICA-TM/MICB C1_2_A</th><th colspan="3">Tumor-related parameters</th></tr>
###xml 983 1001 983 1001 <th xmlns:xlink="http://www.w3.org/1999/xlink">Allele frequencies</th>
###xml 1006 1007 1006 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1001 1013 1001 1013 <th xmlns:xlink="http://www.w3.org/1999/xlink">MIN (<italic>n</italic>&#8201;=&#8201;17)</th>
###xml 1020 1021 1020 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1013 1027 1013 1027 <th xmlns:xlink="http://www.w3.org/1999/xlink">MIN-h (<italic>n</italic>&#8201;=&#8201;10)</th>
###xml 1027 1031 1027 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 1043 1044 1043 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1027 1050 1027 1050 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>KRAS</italic> mutations (<italic>n</italic>&#8201;=&#8201;17)</th>
###xml 983 1050 983 1050 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Allele frequencies</th><th>MIN (<italic>n</italic>&#8201;=&#8201;17)</th><th>MIN-h (<italic>n</italic>&#8201;=&#8201;10)</th><th><italic>KRAS</italic> mutations (<italic>n</italic>&#8201;=&#8201;17)</th></tr>
###xml 940 1050 940 1050 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>MICA-TM/MICB C1_2_A</th><th colspan="3">Tumor-related parameters</th></tr><tr><th>Allele frequencies</th><th>MIN (<italic>n</italic>&#8201;=&#8201;17)</th><th>MIN-h (<italic>n</italic>&#8201;=&#8201;10)</th><th><italic>KRAS</italic> mutations (<italic>n</italic>&#8201;=&#8201;17)</th></tr></thead>
###xml 1050 1064 1050 1064 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">MICA-TM allele</td>
###xml 1050 1064 1050 1064 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">MICA-TM allele</td></tr>
###xml 1064 1067 1064 1067 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A4</td>
###xml 1067 1071 1067 1071 <td xmlns:xlink="http://www.w3.org/1999/xlink">6/21</td>
###xml 1071 1075 1071 1075 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/21</td>
###xml 1075 1079 1075 1079 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/21</td>
###xml 1064 1079 1064 1079 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A4</td><td>6/21</td><td>4/21</td><td>4/21</td></tr>
###xml 1079 1082 1079 1082 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A5</td>
###xml 1082 1086 1082 1086 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/14</td>
###xml 1086 1090 1086 1090 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/14</td>
###xml 1090 1094 1090 1094 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/14</td>
###xml 1079 1094 1079 1094 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A5</td><td>3/14</td><td>3/14</td><td>3/14</td></tr>
###xml 1094 1099 1094 1099 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A5.1</td>
###xml 1099 1104 1099 1104 <td xmlns:xlink="http://www.w3.org/1999/xlink">10/56</td>
###xml 1104 1108 1104 1108 <td xmlns:xlink="http://www.w3.org/1999/xlink">7/56</td>
###xml 1108 1112 1108 1112 <td xmlns:xlink="http://www.w3.org/1999/xlink">9/56</td>
###xml 1094 1112 1094 1112 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A5.1</td><td>10/56</td><td>7/56</td><td>9/56</td></tr>
###xml 1112 1115 1112 1115 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A6</td>
###xml 1115 1119 1115 1119 <td xmlns:xlink="http://www.w3.org/1999/xlink">6/32</td>
###xml 1119 1123 1119 1123 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/32</td>
###xml 1123 1127 1123 1127 <td xmlns:xlink="http://www.w3.org/1999/xlink">9/32</td>
###xml 1112 1127 1112 1127 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A6</td><td>6/32</td><td>3/32</td><td>9/32</td></tr>
###xml 1127 1130 1127 1130 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;A9</td>
###xml 1130 1134 1130 1134 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/16</td>
###xml 1134 1138 1134 1138 <td xmlns:xlink="http://www.w3.org/1999/xlink">2/16</td>
###xml 1138 1142 1138 1142 <td xmlns:xlink="http://www.w3.org/1999/xlink">5/16</td>
###xml 1127 1142 1127 1142 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;A9</td><td>4/16</td><td>2/16</td><td>5/16</td></tr>
###xml 1142 1160 1142 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">MICB C1_2_A allele</td>
###xml 1142 1160 1142 1160 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">MICB C1_2_A allele</td></tr>
###xml 1160 1165 1160 1165 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA14</td>
###xml 1165 1169 1165 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink">7/24</td>
###xml 1169 1173 1169 1173 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/24</td>
###xml 1173 1177 1173 1177 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/24</td>
###xml 1160 1177 1160 1177 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA14</td><td>7/24</td><td>3/24</td><td>3/24</td></tr>
###xml 1177 1182 1177 1182 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA15</td>
###xml 1182 1186 1182 1186 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/28</td>
###xml 1186 1190 1186 1190 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/28</td>
###xml 1190 1194 1190 1194 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/28</td>
###xml 1177 1194 1177 1194 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA15</td><td>4/28</td><td>3/28</td><td>4/28</td></tr>
###xml 1194 1199 1194 1199 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA16</td>
###xml 1199 1203 1199 1203 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 1203 1207 1203 1207 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 1207 1211 1207 1211 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 1194 1211 1194 1211 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA16</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr>
###xml 1211 1216 1211 1216 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA17</td>
###xml 1216 1220 1216 1220 <td xmlns:xlink="http://www.w3.org/1999/xlink">2/17</td>
###xml 1220 1224 1220 1224 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/17</td>
###xml 1224 1228 1224 1228 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/17</td>
###xml 1211 1228 1211 1228 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA17</td><td>2/17</td><td>1/17</td><td>3/17</td></tr>
###xml 1228 1233 1228 1233 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA18</td>
###xml 1233 1237 1233 1237 <td xmlns:xlink="http://www.w3.org/1999/xlink">2/11</td>
###xml 1237 1241 1237 1241 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/11</td>
###xml 1241 1245 1241 1245 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/11</td>
###xml 1228 1245 1228 1245 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA18</td><td>2/11</td><td>1/11</td><td>3/11</td></tr>
###xml 1245 1250 1245 1250 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA19</td>
###xml 1250 1253 1250 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/5</td>
###xml 1253 1256 1253 1256 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/5</td>
###xml 1256 1259 1256 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/5</td>
###xml 1245 1259 1245 1259 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA19</td><td>1/5</td><td>1/5</td><td>1/5</td></tr>
###xml 1259 1264 1259 1264 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA20</td>
###xml 1264 1267 1264 1267 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/6</td>
###xml 1267 1270 1267 1270 <td xmlns:xlink="http://www.w3.org/1999/xlink">0/6</td>
###xml 1270 1273 1270 1273 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/6</td>
###xml 1259 1273 1259 1273 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA20</td><td>1/6</td><td>0/6</td><td>1/6</td></tr>
###xml 1273 1278 1273 1278 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA21</td>
###xml 1278 1282 1278 1282 <td xmlns:xlink="http://www.w3.org/1999/xlink">5/13</td>
###xml 1282 1287 1282 1287 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/13*</td>
###xml 1287 1291 1287 1291 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/13</td>
###xml 1273 1291 1273 1291 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA21</td><td>5/13</td><td>4/13*</td><td>4/13</td></tr>
###xml 1291 1296 1291 1296 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA22</td>
###xml 1296 1299 1296 1299 <td xmlns:xlink="http://www.w3.org/1999/xlink">2/7</td>
###xml 1299 1302 1299 1302 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/7</td>
###xml 1302 1305 1302 1305 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/7</td>
###xml 1291 1305 1291 1305 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA22</td><td>2/7</td><td>1/7</td><td>3/7</td></tr>
###xml 1305 1310 1305 1310 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA23</td>
###xml 1310 1313 1310 1313 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/9</td>
###xml 1313 1316 1313 1316 <td xmlns:xlink="http://www.w3.org/1999/xlink">0/9</td>
###xml 1316 1319 1316 1319 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/9</td>
###xml 1305 1319 1305 1319 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA23</td><td>1/9</td><td>0/9</td><td>4/9</td></tr>
###xml 1319 1324 1319 1324 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA24</td>
###xml 1324 1328 1324 1328 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/24</td>
###xml 1328 1332 1328 1332 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/24</td>
###xml 1332 1336 1332 1336 <td xmlns:xlink="http://www.w3.org/1999/xlink">4/24</td>
###xml 1319 1336 1319 1336 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA24</td><td>4/24</td><td>4/24</td><td>4/24</td></tr>
###xml 1336 1341 1336 1341 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA25</td>
###xml 1341 1344 1341 1344 <td xmlns:xlink="http://www.w3.org/1999/xlink">1/6</td>
###xml 1344 1347 1344 1347 <td xmlns:xlink="http://www.w3.org/1999/xlink">0/6</td>
###xml 1347 1350 1347 1350 <td xmlns:xlink="http://www.w3.org/1999/xlink">3/6</td>
###xml 1336 1350 1336 1350 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA25</td><td>1/6</td><td>0/6</td><td>3/6</td></tr>
###xml 1350 1355 1350 1355 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA26</td>
###xml 1355 1359 1355 1359 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 1359 1363 1359 1363 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 1363 1367 1363 1367 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 1350 1367 1350 1367 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA26</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr>
###xml 1367 1372 1367 1372 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CA27</td>
###xml 1372 1376 1372 1376 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 1376 1380 1376 1380 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 1380 1384 1380 1384 <td xmlns:xlink="http://www.w3.org/1999/xlink">n.d.</td>
###xml 1367 1384 1367 1384 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CA27</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr>
###xml 1050 1384 1050 1384 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="4">MICA-TM allele</td></tr><tr><td>&#160;A4</td><td>6/21</td><td>4/21</td><td>4/21</td></tr><tr><td>&#160;A5</td><td>3/14</td><td>3/14</td><td>3/14</td></tr><tr><td>&#160;A5.1</td><td>10/56</td><td>7/56</td><td>9/56</td></tr><tr><td>&#160;A6</td><td>6/32</td><td>3/32</td><td>9/32</td></tr><tr><td>&#160;A9</td><td>4/16</td><td>2/16</td><td>5/16</td></tr><tr><td colspan="4">MICB C1_2_A allele</td></tr><tr><td>&#160;CA14</td><td>7/24</td><td>3/24</td><td>3/24</td></tr><tr><td>&#160;CA15</td><td>4/28</td><td>3/28</td><td>4/28</td></tr><tr><td>&#160;CA16</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr><tr><td>&#160;CA17</td><td>2/17</td><td>1/17</td><td>3/17</td></tr><tr><td>&#160;CA18</td><td>2/11</td><td>1/11</td><td>3/11</td></tr><tr><td>&#160;CA19</td><td>1/5</td><td>1/5</td><td>1/5</td></tr><tr><td>&#160;CA20</td><td>1/6</td><td>0/6</td><td>1/6</td></tr><tr><td>&#160;CA21</td><td>5/13</td><td>4/13*</td><td>4/13</td></tr><tr><td>&#160;CA22</td><td>2/7</td><td>1/7</td><td>3/7</td></tr><tr><td>&#160;CA23</td><td>1/9</td><td>0/9</td><td>4/9</td></tr><tr><td>&#160;CA24</td><td>4/24</td><td>4/24</td><td>4/24</td></tr><tr><td>&#160;CA25</td><td>1/6</td><td>0/6</td><td>3/6</td></tr><tr><td>&#160;CA26</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr><tr><td>&#160;CA27</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr></tbody>
###xml 940 1384 940 1384 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>MICA-TM/MICB C1_2_A</th><th colspan="3">Tumor-related parameters</th></tr><tr><th>Allele frequencies</th><th>MIN (<italic>n</italic>&#8201;=&#8201;17)</th><th>MIN-h (<italic>n</italic>&#8201;=&#8201;10)</th><th><italic>KRAS</italic> mutations (<italic>n</italic>&#8201;=&#8201;17)</th></tr></thead><tbody><tr><td colspan="4">MICA-TM allele</td></tr><tr><td>&#160;A4</td><td>6/21</td><td>4/21</td><td>4/21</td></tr><tr><td>&#160;A5</td><td>3/14</td><td>3/14</td><td>3/14</td></tr><tr><td>&#160;A5.1</td><td>10/56</td><td>7/56</td><td>9/56</td></tr><tr><td>&#160;A6</td><td>6/32</td><td>3/32</td><td>9/32</td></tr><tr><td>&#160;A9</td><td>4/16</td><td>2/16</td><td>5/16</td></tr><tr><td colspan="4">MICB C1_2_A allele</td></tr><tr><td>&#160;CA14</td><td>7/24</td><td>3/24</td><td>3/24</td></tr><tr><td>&#160;CA15</td><td>4/28</td><td>3/28</td><td>4/28</td></tr><tr><td>&#160;CA16</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr><tr><td>&#160;CA17</td><td>2/17</td><td>1/17</td><td>3/17</td></tr><tr><td>&#160;CA18</td><td>2/11</td><td>1/11</td><td>3/11</td></tr><tr><td>&#160;CA19</td><td>1/5</td><td>1/5</td><td>1/5</td></tr><tr><td>&#160;CA20</td><td>1/6</td><td>0/6</td><td>1/6</td></tr><tr><td>&#160;CA21</td><td>5/13</td><td>4/13*</td><td>4/13</td></tr><tr><td>&#160;CA22</td><td>2/7</td><td>1/7</td><td>3/7</td></tr><tr><td>&#160;CA23</td><td>1/9</td><td>0/9</td><td>4/9</td></tr><tr><td>&#160;CA24</td><td>4/24</td><td>4/24</td><td>4/24</td></tr><tr><td>&#160;CA25</td><td>1/6</td><td>0/6</td><td>3/6</td></tr><tr><td>&#160;CA26</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr><tr><td>&#160;CA27</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr></tbody></table>
###xml 1384 1803 1384 1803 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Microsatellite instability (MIN) was defined as altered lengths of PCR products typing five defined mono- and dinucleotide repeat markers. Tumor MIN was considered when at least one repeat locus showed altered length and high microsatellite instability (MIN-h) when two or more microsatellite markers showed tumor DNA replication errors. For analysis, only MICA-TM and MICB C1_2_A allele frequencies &gt;5% were considered</p>
###xml 1804 1805 1804 1805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1803 1813 1803 1813 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">*<italic>p</italic>&#8201;=&#8201;0.047</p>
###xml 1384 1813 1384 1813 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Microsatellite instability (MIN) was defined as altered lengths of PCR products typing five defined mono- and dinucleotide repeat markers. Tumor MIN was considered when at least one repeat locus showed altered length and high microsatellite instability (MIN-h) when two or more microsatellite markers showed tumor DNA replication errors. For analysis, only MICA-TM and MICB C1_2_A allele frequencies &gt;5% were considered</p><p textid="41">*<italic>p</italic>&#8201;=&#8201;0.047</p></table-wrap-foot>
###xml 791 1813 791 1813 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table III</label><caption><p textid="39">MICA-TM and MICB C1_2_A Polymorphisms in Colorectal Cancer Patients with Regard to Tumor Microsatellite Stability or <italic>KRAS</italic> Codon 12 Mutations</p></caption><table frame="hsides" rules="groups"><thead><tr><th>MICA-TM/MICB C1_2_A</th><th colspan="3">Tumor-related parameters</th></tr><tr><th>Allele frequencies</th><th>MIN (<italic>n</italic>&#8201;=&#8201;17)</th><th>MIN-h (<italic>n</italic>&#8201;=&#8201;10)</th><th><italic>KRAS</italic> mutations (<italic>n</italic>&#8201;=&#8201;17)</th></tr></thead><tbody><tr><td colspan="4">MICA-TM allele</td></tr><tr><td>&#160;A4</td><td>6/21</td><td>4/21</td><td>4/21</td></tr><tr><td>&#160;A5</td><td>3/14</td><td>3/14</td><td>3/14</td></tr><tr><td>&#160;A5.1</td><td>10/56</td><td>7/56</td><td>9/56</td></tr><tr><td>&#160;A6</td><td>6/32</td><td>3/32</td><td>9/32</td></tr><tr><td>&#160;A9</td><td>4/16</td><td>2/16</td><td>5/16</td></tr><tr><td colspan="4">MICB C1_2_A allele</td></tr><tr><td>&#160;CA14</td><td>7/24</td><td>3/24</td><td>3/24</td></tr><tr><td>&#160;CA15</td><td>4/28</td><td>3/28</td><td>4/28</td></tr><tr><td>&#160;CA16</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr><tr><td>&#160;CA17</td><td>2/17</td><td>1/17</td><td>3/17</td></tr><tr><td>&#160;CA18</td><td>2/11</td><td>1/11</td><td>3/11</td></tr><tr><td>&#160;CA19</td><td>1/5</td><td>1/5</td><td>1/5</td></tr><tr><td>&#160;CA20</td><td>1/6</td><td>0/6</td><td>1/6</td></tr><tr><td>&#160;CA21</td><td>5/13</td><td>4/13*</td><td>4/13</td></tr><tr><td>&#160;CA22</td><td>2/7</td><td>1/7</td><td>3/7</td></tr><tr><td>&#160;CA23</td><td>1/9</td><td>0/9</td><td>4/9</td></tr><tr><td>&#160;CA24</td><td>4/24</td><td>4/24</td><td>4/24</td></tr><tr><td>&#160;CA25</td><td>1/6</td><td>0/6</td><td>3/6</td></tr><tr><td>&#160;CA26</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr><tr><td>&#160;CA27</td><td>n.d.</td><td>n.d.</td><td>n.d.</td></tr></tbody></table><table-wrap-foot><p textid="40">Microsatellite instability (MIN) was defined as altered lengths of PCR products typing five defined mono- and dinucleotide repeat markers. Tumor MIN was considered when at least one repeat locus showed altered length and high microsatellite instability (MIN-h) when two or more microsatellite markers showed tumor DNA replication errors. For analysis, only MICA-TM and MICB C1_2_A allele frequencies &gt;5% were considered</p><p textid="41">*<italic>p</italic>&#8201;=&#8201;0.047</p></table-wrap-foot></table-wrap>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
###xml 859 867 <span type="species:ncbi:9606">Patients</span>
A trend for an increased frequency of the MICB C1_2_A CA21 allele was observed in patients with colorectal tumors showing high microsatellite instability as defined by different lengths of PCR products in more than two markers (p = 0.047; Table III). Mutations in the KRAS oncogene were detected in 17 colorectal cancer samples (20.9%). The KRAS codon 12 mutation in tumor DNA samples were determined by sequencing the PCR-generated fragment, and the following mutations (12C: n = 3; 12D: n = 4; 12 V: n = 7; 12 S: n = 2) were detected. No correlation of MICA-TM alleles with the presence of KRAS mutations was seen in the investigated colorectal cancer patients. For MICB C1_2_A alleles, only a trend toward an association with KRAS mutations was observed for the CA 23 allele (p = 0.087). Table IIIMICA-TM and MICB C1_2_A Polymorphisms in Colorectal Cancer Patients with Regard to Tumor Microsatellite Stability or KRAS Codon 12 MutationsMICA-TM/MICB C1_2_ATumor-related parametersAllele frequenciesMIN (n = 17)MIN-h (n = 10)KRAS mutations (n = 17)MICA-TM allele A46/214/214/21 A53/143/143/14 A5.110/567/569/56 A66/323/329/32 A94/162/165/16MICB C1_2_A allele CA147/243/243/24 CA154/283/284/28 CA16n.d.n.d.n.d. CA172/171/173/17 CA182/111/113/11 CA191/51/51/5 CA201/60/61/6 CA215/134/13*4/13 CA222/71/73/7 CA231/90/94/9 CA244/244/244/24 CA251/60/63/6 CA26n.d.n.d.n.d. CA27n.d.n.d.n.d.Microsatellite instability (MIN) was defined as altered lengths of PCR products typing five defined mono- and dinucleotide repeat markers. Tumor MIN was considered when at least one repeat locus showed altered length and high microsatellite instability (MIN-h) when two or more microsatellite markers showed tumor DNA replication errors. For analysis, only MICA-TM and MICB C1_2_A allele frequencies >5% were considered*p = 0.047
###end p 38
###begin p 39
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 59 67 <span type="species:ncbi:9606">Patients</span>
MICA-TM and MICB C1_2_A Polymorphisms in Colorectal Cancer Patients with Regard to Tumor Microsatellite Stability or KRAS Codon 12 Mutations
###end p 39
###begin p 40
Microsatellite instability (MIN) was defined as altered lengths of PCR products typing five defined mono- and dinucleotide repeat markers. Tumor MIN was considered when at least one repeat locus showed altered length and high microsatellite instability (MIN-h) when two or more microsatellite markers showed tumor DNA replication errors. For analysis, only MICA-TM and MICB C1_2_A allele frequencies >5% were considered
###end p 40
###begin p 41
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
*p = 0.047
###end p 41
###begin title 42
Analysis of Survival Times
###end title 42
###begin p 43
###xml 272 273 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 391 392 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 399 400 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 526 527 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 554 555 550 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 617 619 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">IV</xref>
###xml 776 777 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 792 793 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1085 1086 1081 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1161 1162 1157 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1211 1219 1207 1215 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table IV</label>
###xml 1219 1257 1215 1253 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Survival of Colorectal Cancer Patients</p>
###xml 1219 1257 1215 1253 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Survival of Colorectal Cancer Patients</p></caption>
###xml 1257 1281 1253 1277 <th xmlns:xlink="http://www.w3.org/1999/xlink">Tumor-related parameters</th>
###xml 1281 1317 1277 1311 <th xmlns:xlink="http://www.w3.org/1999/xlink">Survival times (mean &#177; SD; months)</th>
###xml 1317 1342 1311 1336 <th xmlns:xlink="http://www.w3.org/1999/xlink">(95% Confidence interval)</th>
###xml 1342 1343 1336 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1342 1349 1336 1343 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 1257 1349 1253 1343 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Tumor-related parameters</th><th>Survival times (mean &#177; SD; months)</th><th>(95% Confidence interval)</th><th><italic>p</italic> value</th></tr>
###xml 1257 1349 1253 1343 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Tumor-related parameters</th><th>Survival times (mean &#177; SD; months)</th><th>(95% Confidence interval)</th><th><italic>p</italic> value</th></tr></thead>
###xml 1349 1363 1343 1357 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Tumor invasion</td>
###xml 1349 1363 1343 1357 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Tumor invasion</td></tr>
###xml 1370 1371 1364 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1363 1377 1357 1371 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;13)</td>
###xml 1377 1389 1371 1381 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">85.0&#8201;&#177;&#8201;9.6</td>
###xml 1389 1401 1381 1393 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(66.2&#8211;103.9)</td>
###xml 1401 1406 1393 1398 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">0.113</td>
###xml 1363 1406 1357 1398 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;13)</td><td char="&#177;" align="char">85.0&#8201;&#177;&#8201;9.6</td><td char="(" align="char">(66.2&#8211;103.9)</td><td char="." align="char" rowspan="2">0.113</td></tr>
###xml 1413 1414 1405 1406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1406 1420 1398 1412 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;48)</td>
###xml 1420 1432 1412 1422 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">69.0&#8201;&#177;&#8201;6.0</td>
###xml 1432 1443 1422 1433 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(57.1&#8211;80.8)</td>
###xml 1406 1443 1398 1433 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;48)</td><td char="&#177;" align="char">69.0&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(57.1&#8211;80.8)</td></tr>
###xml 1443 1465 1433 1455 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Lymph node involvement</td>
###xml 1443 1465 1433 1455 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Lymph node involvement</td></tr>
###xml 1470 1471 1460 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1465 1477 1455 1467 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;N0 (<italic>n</italic>&#8201;=&#8201;34)</td>
###xml 1477 1489 1467 1477 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">88.8&#8201;&#177;&#8201;5.4</td>
###xml 1489 1500 1477 1488 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(78.1&#8211;99.4)</td>
###xml 1500 1505 1488 1493 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="3">0.005</td>
###xml 1465 1505 1455 1493 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;N0 (<italic>n</italic>&#8201;=&#8201;34)</td><td char="&#177;" align="char">88.8&#8201;&#177;&#8201;5.4</td><td char="(" align="char">(78.1&#8211;99.4)</td><td char="." align="char" rowspan="3">0.005</td></tr>
###xml 1510 1511 1498 1499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1505 1517 1493 1505 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;N1 (<italic>n</italic>&#8201;=&#8201;18)</td>
###xml 1517 1529 1505 1515 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">65.3&#8201;&#177;&#8201;8.9</td>
###xml 1529 1540 1515 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(47.7&#8211;82.8)</td>
###xml 1505 1540 1493 1526 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;N1 (<italic>n</italic>&#8201;=&#8201;18)</td><td char="&#177;" align="char">65.3&#8201;&#177;&#8201;8.9</td><td char="(" align="char">(47.7&#8211;82.8)</td></tr>
###xml 1545 1546 1531 1532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1540 1551 1526 1537 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;N2 (<italic>n</italic>&#8201;=&#8201;9)</td>
###xml 1551 1563 1537 1547 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">25.9&#8201;&#177;&#8201;5.2</td>
###xml 1563 1573 1547 1557 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(6.9&#8211;44.9)</td>
###xml 1540 1573 1526 1557 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;N2 (<italic>n</italic>&#8201;=&#8201;9)</td><td char="&#177;" align="char">25.9&#8201;&#177;&#8201;5.2</td><td char="(" align="char">(6.9&#8211;44.9)</td></tr>
###xml 1573 1584 1557 1568 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">UICC stages</td>
###xml 1573 1584 1557 1568 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">UICC stages</td></tr>
###xml 1596 1597 1580 1581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1584 1603 1568 1587 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;30)</td>
###xml 1603 1615 1587 1597 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">93.9&#8201;&#177;&#8201;4.8</td>
###xml 1615 1627 1597 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(84.4&#8211;103.4)</td>
###xml 1627 1627 1609 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1584 1627 1568 1609 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;30)</td><td char="&#177;" align="char">93.9&#8201;&#177;&#8201;4.8</td><td char="(" align="char">(84.4&#8211;103.4)</td><td/></tr>
###xml 1641 1642 1623 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1627 1648 1609 1630 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;31)</td>
###xml 1648 1660 1630 1640 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">52.7&#8201;&#177;&#8201;7.3</td>
###xml 1660 1671 1640 1651 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(38.3&#8211;67.0)</td>
###xml 1671 1677 1651 1657 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1627 1677 1609 1657 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;31)</td><td char="&#177;" align="char">52.7&#8201;&#177;&#8201;7.3</td><td char="(" align="char">(38.3&#8211;67.0)</td><td char="." align="char">&lt;0.001</td></tr>
###xml 1677 1679 1657 1659 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">A4</td>
###xml 1677 1679 1657 1659 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">A4</td></tr>
###xml 1684 1685 1664 1665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1679 1691 1659 1671 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td>
###xml 1691 1703 1671 1681 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">80.6&#8201;&#177;&#8201;5.6</td>
###xml 1703 1714 1681 1692 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(69.7&#8211;91.6)</td>
###xml 1714 1714 1692 1692 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1679 1714 1659 1692 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td><td char="&#177;" align="char">80.6&#8201;&#177;&#8201;5.6</td><td char="(" align="char">(69.7&#8211;91.6)</td><td/></tr>
###xml 1720 1721 1698 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1714 1727 1692 1705 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td>
###xml 1727 1740 1705 1716 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">51.9&#8201;&#177;&#8201;10.9</td>
###xml 1740 1751 1716 1727 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(30.5&#8211;73.2)</td>
###xml 1751 1756 1727 1732 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.015</td>
###xml 1714 1756 1692 1732 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td><td char="&#177;" align="char">51.9&#8201;&#177;&#8201;10.9</td><td char="(" align="char">(30.5&#8211;73.2)</td><td char="." align="char">0.015</td></tr>
###xml 1756 1758 1732 1734 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">A5</td>
###xml 1756 1758 1732 1734 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">A5</td></tr>
###xml 1763 1764 1739 1740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1758 1770 1734 1746 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td>
###xml 1770 1782 1746 1756 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">56.0&#8201;&#177;&#8201;6.1</td>
###xml 1782 1793 1756 1767 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(56.0&#8211;80.2)</td>
###xml 1793 1793 1767 1767 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1758 1793 1734 1767 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td><td char="&#177;" align="char">56.0&#8201;&#177;&#8201;6.1</td><td char="(" align="char">(56.0&#8211;80.2)</td><td/></tr>
###xml 1799 1800 1773 1774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1793 1806 1767 1780 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td>
###xml 1806 1818 1780 1790 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">87.4&#8201;&#177;&#8201;6.3</td>
###xml 1818 1829 1790 1801 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(75.0&#8211;99.7)</td>
###xml 1829 1834 1801 1806 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.074</td>
###xml 1793 1834 1767 1806 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td><td char="&#177;" align="char">87.4&#8201;&#177;&#8201;6.3</td><td char="(" align="char">(75.0&#8211;99.7)</td><td char="." align="char">0.074</td></tr>
###xml 1834 1838 1806 1810 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">A5.1</td>
###xml 1834 1838 1806 1810 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">A5.1</td></tr>
###xml 1843 1844 1815 1816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1838 1850 1810 1822 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;19)</td>
###xml 1850 1862 1822 1832 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">65.2&#8201;&#177;&#8201;9.8</td>
###xml 1862 1873 1832 1843 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(45.9&#8211;84.5)</td>
###xml 1873 1873 1843 1843 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1838 1873 1810 1843 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;19)</td><td char="&#177;" align="char">65.2&#8201;&#177;&#8201;9.8</td><td char="(" align="char">(45.9&#8211;84.5)</td><td/></tr>
###xml 1879 1880 1849 1850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1873 1886 1843 1856 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;42)</td>
###xml 1886 1898 1856 1866 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">75.2&#8201;&#177;&#8201;5.7</td>
###xml 1898 1909 1866 1877 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(63.9&#8211;86.6)</td>
###xml 1909 1914 1877 1882 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.257</td>
###xml 1873 1914 1843 1882 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">75.2&#8201;&#177;&#8201;5.7</td><td char="(" align="char">(63.9&#8211;86.6)</td><td char="." align="char">0.257</td></tr>
###xml 1914 1916 1882 1884 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">A9</td>
###xml 1914 1916 1882 1884 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">A9</td></tr>
###xml 1921 1922 1889 1890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1916 1928 1884 1896 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;48)</td>
###xml 1928 1940 1896 1906 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">75.9&#8201;&#177;&#8201;5.5</td>
###xml 1940 1951 1906 1917 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(65.0&#8211;86.8)</td>
###xml 1951 1951 1917 1917 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1916 1951 1884 1917 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;48)</td><td char="&#177;" align="char">75.9&#8201;&#177;&#8201;5.5</td><td char="(" align="char">(65.0&#8211;86.8)</td><td/></tr>
###xml 1957 1958 1923 1924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1951 1964 1917 1930 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;13)</td>
###xml 1964 1977 1930 1941 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">59.5&#8201;&#177;&#8201;10.6</td>
###xml 1977 1988 1941 1952 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(38.7&#8211;80.3)</td>
###xml 1988 1993 1952 1957 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.106</td>
###xml 1951 1993 1917 1957 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;13)</td><td char="&#177;" align="char">59.5&#8201;&#177;&#8201;10.6</td><td char="(" align="char">(38.7&#8211;80.3)</td><td char="." align="char">0.106</td></tr>
###xml 1993 1997 1957 1961 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">CA24</td>
###xml 1993 1997 1957 1961 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">CA24</td></tr>
###xml 2002 2003 1966 1967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1997 2009 1961 1973 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td>
###xml 2009 2021 1973 1983 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">66.7&#8201;&#177;&#8201;6.1</td>
###xml 2021 2032 1983 1994 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(54.7&#8211;78.7)</td>
###xml 2032 2032 1994 1994 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1997 2032 1961 1994 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">66.7&#8201;&#177;&#8201;6.1</td><td char="(" align="char">(54.7&#8211;78.7)</td><td/></tr>
###xml 2038 2039 2000 2001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2032 2045 1994 2007 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;19)</td>
###xml 2045 2057 2007 2017 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">84.3&#8201;&#177;&#8201;8.6</td>
###xml 2057 2069 2017 2029 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(67.4&#8211;101.3)</td>
###xml 2069 2074 2029 2034 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.108</td>
###xml 2032 2074 1994 2034 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;19)</td><td char="&#177;" align="char">84.3&#8201;&#177;&#8201;8.6</td><td char="(" align="char">(67.4&#8211;101.3)</td><td char="." align="char">0.108</td></tr>
###xml 2074 2114 2034 2072 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Microsatellite instability (&#8805;1 marker)</td>
###xml 2074 2114 2034 2072 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Microsatellite instability (&#8805;1 marker)</td></tr>
###xml 2119 2120 2077 2078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2114 2126 2072 2084 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;54)</td>
###xml 2126 2138 2084 2094 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">71.7&#8201;&#177;&#8201;5.7</td>
###xml 2138 2149 2094 2105 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(60.4&#8211;83.0)</td>
###xml 2149 2149 2105 2105 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2114 2149 2072 2105 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;54)</td><td char="&#177;" align="char">71.7&#8201;&#177;&#8201;5.7</td><td char="(" align="char">(60.4&#8211;83.0)</td><td/></tr>
###xml 2155 2156 2111 2112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2149 2161 2105 2117 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;7)</td>
###xml 2161 2173 2117 2127 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">82.2&#8201;&#177;&#8201;9.5</td>
###xml 2173 2185 2127 2139 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(63.6&#8211;100.9)</td>
###xml 2185 2190 2139 2144 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.410</td>
###xml 2149 2190 2105 2144 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;7)</td><td char="&#177;" align="char">82.2&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(63.6&#8211;100.9)</td><td char="." align="char">0.410</td></tr>
###xml 2190 2194 2144 2148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 2190 2213 2144 2167 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4"><italic>KRAS</italic> codon 12 mutations</td>
###xml 2190 2213 2144 2167 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4"><italic>KRAS</italic> codon 12 mutations</td></tr>
###xml 2218 2219 2172 2173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2213 2225 2167 2179 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;44)</td>
###xml 2225 2237 2179 2189 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">78.7&#8201;&#177;&#8201;6.0</td>
###xml 2237 2248 2189 2200 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(66.9&#8211;90.4)</td>
###xml 2248 2248 2200 2200 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2213 2248 2167 2200 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;44)</td><td char="&#177;" align="char">78.7&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(66.9&#8211;90.4)</td><td/></tr>
###xml 2254 2255 2206 2207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2248 2261 2200 2213 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;17)</td>
###xml 2261 2273 2213 2223 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">58.7&#8201;&#177;&#8201;9.5</td>
###xml 2273 2284 2223 2234 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(40.0&#8211;77.5)</td>
###xml 2284 2289 2234 2239 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.093</td>
###xml 2248 2289 2200 2239 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;17)</td><td char="&#177;" align="char">58.7&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(40.0&#8211;77.5)</td><td char="." align="char">0.093</td></tr>
###xml 1349 2289 1343 2239 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="4">Tumor invasion</td></tr><tr><td>&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;13)</td><td char="&#177;" align="char">85.0&#8201;&#177;&#8201;9.6</td><td char="(" align="char">(66.2&#8211;103.9)</td><td char="." align="char" rowspan="2">0.113</td></tr><tr><td>&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;48)</td><td char="&#177;" align="char">69.0&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(57.1&#8211;80.8)</td></tr><tr><td colspan="4">Lymph node involvement</td></tr><tr><td>&#160;N0 (<italic>n</italic>&#8201;=&#8201;34)</td><td char="&#177;" align="char">88.8&#8201;&#177;&#8201;5.4</td><td char="(" align="char">(78.1&#8211;99.4)</td><td char="." align="char" rowspan="3">0.005</td></tr><tr><td>&#160;N1 (<italic>n</italic>&#8201;=&#8201;18)</td><td char="&#177;" align="char">65.3&#8201;&#177;&#8201;8.9</td><td char="(" align="char">(47.7&#8211;82.8)</td></tr><tr><td>&#160;N2 (<italic>n</italic>&#8201;=&#8201;9)</td><td char="&#177;" align="char">25.9&#8201;&#177;&#8201;5.2</td><td char="(" align="char">(6.9&#8211;44.9)</td></tr><tr><td colspan="4">UICC stages</td></tr><tr><td>&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;30)</td><td char="&#177;" align="char">93.9&#8201;&#177;&#8201;4.8</td><td char="(" align="char">(84.4&#8211;103.4)</td><td/></tr><tr><td>&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;31)</td><td char="&#177;" align="char">52.7&#8201;&#177;&#8201;7.3</td><td char="(" align="char">(38.3&#8211;67.0)</td><td char="." align="char">&lt;0.001</td></tr><tr><td colspan="4">A4</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td><td char="&#177;" align="char">80.6&#8201;&#177;&#8201;5.6</td><td char="(" align="char">(69.7&#8211;91.6)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td><td char="&#177;" align="char">51.9&#8201;&#177;&#8201;10.9</td><td char="(" align="char">(30.5&#8211;73.2)</td><td char="." align="char">0.015</td></tr><tr><td colspan="4">A5</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td><td char="&#177;" align="char">56.0&#8201;&#177;&#8201;6.1</td><td char="(" align="char">(56.0&#8211;80.2)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td><td char="&#177;" align="char">87.4&#8201;&#177;&#8201;6.3</td><td char="(" align="char">(75.0&#8211;99.7)</td><td char="." align="char">0.074</td></tr><tr><td colspan="4">A5.1</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;19)</td><td char="&#177;" align="char">65.2&#8201;&#177;&#8201;9.8</td><td char="(" align="char">(45.9&#8211;84.5)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">75.2&#8201;&#177;&#8201;5.7</td><td char="(" align="char">(63.9&#8211;86.6)</td><td char="." align="char">0.257</td></tr><tr><td colspan="4">A9</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;48)</td><td char="&#177;" align="char">75.9&#8201;&#177;&#8201;5.5</td><td char="(" align="char">(65.0&#8211;86.8)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;13)</td><td char="&#177;" align="char">59.5&#8201;&#177;&#8201;10.6</td><td char="(" align="char">(38.7&#8211;80.3)</td><td char="." align="char">0.106</td></tr><tr><td colspan="4">CA24</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">66.7&#8201;&#177;&#8201;6.1</td><td char="(" align="char">(54.7&#8211;78.7)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;19)</td><td char="&#177;" align="char">84.3&#8201;&#177;&#8201;8.6</td><td char="(" align="char">(67.4&#8211;101.3)</td><td char="." align="char">0.108</td></tr><tr><td colspan="4">Microsatellite instability (&#8805;1 marker)</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;54)</td><td char="&#177;" align="char">71.7&#8201;&#177;&#8201;5.7</td><td char="(" align="char">(60.4&#8211;83.0)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;7)</td><td char="&#177;" align="char">82.2&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(63.6&#8211;100.9)</td><td char="." align="char">0.410</td></tr><tr><td colspan="4"><italic>KRAS</italic> codon 12 mutations</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;44)</td><td char="&#177;" align="char">78.7&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(66.9&#8211;90.4)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;17)</td><td char="&#177;" align="char">58.7&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(40.0&#8211;77.5)</td><td char="." align="char">0.093</td></tr></tbody>
###xml 1257 2289 1253 2239 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Tumor-related parameters</th><th>Survival times (mean &#177; SD; months)</th><th>(95% Confidence interval)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Tumor invasion</td></tr><tr><td>&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;13)</td><td char="&#177;" align="char">85.0&#8201;&#177;&#8201;9.6</td><td char="(" align="char">(66.2&#8211;103.9)</td><td char="." align="char" rowspan="2">0.113</td></tr><tr><td>&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;48)</td><td char="&#177;" align="char">69.0&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(57.1&#8211;80.8)</td></tr><tr><td colspan="4">Lymph node involvement</td></tr><tr><td>&#160;N0 (<italic>n</italic>&#8201;=&#8201;34)</td><td char="&#177;" align="char">88.8&#8201;&#177;&#8201;5.4</td><td char="(" align="char">(78.1&#8211;99.4)</td><td char="." align="char" rowspan="3">0.005</td></tr><tr><td>&#160;N1 (<italic>n</italic>&#8201;=&#8201;18)</td><td char="&#177;" align="char">65.3&#8201;&#177;&#8201;8.9</td><td char="(" align="char">(47.7&#8211;82.8)</td></tr><tr><td>&#160;N2 (<italic>n</italic>&#8201;=&#8201;9)</td><td char="&#177;" align="char">25.9&#8201;&#177;&#8201;5.2</td><td char="(" align="char">(6.9&#8211;44.9)</td></tr><tr><td colspan="4">UICC stages</td></tr><tr><td>&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;30)</td><td char="&#177;" align="char">93.9&#8201;&#177;&#8201;4.8</td><td char="(" align="char">(84.4&#8211;103.4)</td><td/></tr><tr><td>&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;31)</td><td char="&#177;" align="char">52.7&#8201;&#177;&#8201;7.3</td><td char="(" align="char">(38.3&#8211;67.0)</td><td char="." align="char">&lt;0.001</td></tr><tr><td colspan="4">A4</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td><td char="&#177;" align="char">80.6&#8201;&#177;&#8201;5.6</td><td char="(" align="char">(69.7&#8211;91.6)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td><td char="&#177;" align="char">51.9&#8201;&#177;&#8201;10.9</td><td char="(" align="char">(30.5&#8211;73.2)</td><td char="." align="char">0.015</td></tr><tr><td colspan="4">A5</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td><td char="&#177;" align="char">56.0&#8201;&#177;&#8201;6.1</td><td char="(" align="char">(56.0&#8211;80.2)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td><td char="&#177;" align="char">87.4&#8201;&#177;&#8201;6.3</td><td char="(" align="char">(75.0&#8211;99.7)</td><td char="." align="char">0.074</td></tr><tr><td colspan="4">A5.1</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;19)</td><td char="&#177;" align="char">65.2&#8201;&#177;&#8201;9.8</td><td char="(" align="char">(45.9&#8211;84.5)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">75.2&#8201;&#177;&#8201;5.7</td><td char="(" align="char">(63.9&#8211;86.6)</td><td char="." align="char">0.257</td></tr><tr><td colspan="4">A9</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;48)</td><td char="&#177;" align="char">75.9&#8201;&#177;&#8201;5.5</td><td char="(" align="char">(65.0&#8211;86.8)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;13)</td><td char="&#177;" align="char">59.5&#8201;&#177;&#8201;10.6</td><td char="(" align="char">(38.7&#8211;80.3)</td><td char="." align="char">0.106</td></tr><tr><td colspan="4">CA24</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">66.7&#8201;&#177;&#8201;6.1</td><td char="(" align="char">(54.7&#8211;78.7)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;19)</td><td char="&#177;" align="char">84.3&#8201;&#177;&#8201;8.6</td><td char="(" align="char">(67.4&#8211;101.3)</td><td char="." align="char">0.108</td></tr><tr><td colspan="4">Microsatellite instability (&#8805;1 marker)</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;54)</td><td char="&#177;" align="char">71.7&#8201;&#177;&#8201;5.7</td><td char="(" align="char">(60.4&#8211;83.0)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;7)</td><td char="&#177;" align="char">82.2&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(63.6&#8211;100.9)</td><td char="." align="char">0.410</td></tr><tr><td colspan="4"><italic>KRAS</italic> codon 12 mutations</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;44)</td><td char="&#177;" align="char">78.7&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(66.9&#8211;90.4)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;17)</td><td char="&#177;" align="char">58.7&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(40.0&#8211;77.5)</td><td char="." align="char">0.093</td></tr></tbody></table>
###xml 2506 2507 2456 2457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2289 2611 2239 2561 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Univariate analysis of tumor-related survival times of patients with indicated clinicopathological parameters and selected MICA-TM (A4, A5, A5.1, A9) and MICB C1_2_A (CA24) alleles in patients with colorectal cancer (<italic>n</italic>&#8201;=&#8201;61). Kaplan&#8211;Meier analysis and the log rank test were used for comparisons and statistical evaluation</p>
###xml 2289 2611 2239 2561 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">Univariate analysis of tumor-related survival times of patients with indicated clinicopathological parameters and selected MICA-TM (A4, A5, A5.1, A9) and MICB C1_2_A (CA24) alleles in patients with colorectal cancer (<italic>n</italic>&#8201;=&#8201;61). Kaplan&#8211;Meier analysis and the log rank test were used for comparisons and statistical evaluation</p></table-wrap-foot>
###xml 1211 2611 1207 2561 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table IV</label><caption><p textid="44">Survival of Colorectal Cancer Patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Tumor-related parameters</th><th>Survival times (mean &#177; SD; months)</th><th>(95% Confidence interval)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Tumor invasion</td></tr><tr><td>&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;13)</td><td char="&#177;" align="char">85.0&#8201;&#177;&#8201;9.6</td><td char="(" align="char">(66.2&#8211;103.9)</td><td char="." align="char" rowspan="2">0.113</td></tr><tr><td>&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;48)</td><td char="&#177;" align="char">69.0&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(57.1&#8211;80.8)</td></tr><tr><td colspan="4">Lymph node involvement</td></tr><tr><td>&#160;N0 (<italic>n</italic>&#8201;=&#8201;34)</td><td char="&#177;" align="char">88.8&#8201;&#177;&#8201;5.4</td><td char="(" align="char">(78.1&#8211;99.4)</td><td char="." align="char" rowspan="3">0.005</td></tr><tr><td>&#160;N1 (<italic>n</italic>&#8201;=&#8201;18)</td><td char="&#177;" align="char">65.3&#8201;&#177;&#8201;8.9</td><td char="(" align="char">(47.7&#8211;82.8)</td></tr><tr><td>&#160;N2 (<italic>n</italic>&#8201;=&#8201;9)</td><td char="&#177;" align="char">25.9&#8201;&#177;&#8201;5.2</td><td char="(" align="char">(6.9&#8211;44.9)</td></tr><tr><td colspan="4">UICC stages</td></tr><tr><td>&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;30)</td><td char="&#177;" align="char">93.9&#8201;&#177;&#8201;4.8</td><td char="(" align="char">(84.4&#8211;103.4)</td><td/></tr><tr><td>&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;31)</td><td char="&#177;" align="char">52.7&#8201;&#177;&#8201;7.3</td><td char="(" align="char">(38.3&#8211;67.0)</td><td char="." align="char">&lt;0.001</td></tr><tr><td colspan="4">A4</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td><td char="&#177;" align="char">80.6&#8201;&#177;&#8201;5.6</td><td char="(" align="char">(69.7&#8211;91.6)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td><td char="&#177;" align="char">51.9&#8201;&#177;&#8201;10.9</td><td char="(" align="char">(30.5&#8211;73.2)</td><td char="." align="char">0.015</td></tr><tr><td colspan="4">A5</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;47)</td><td char="&#177;" align="char">56.0&#8201;&#177;&#8201;6.1</td><td char="(" align="char">(56.0&#8211;80.2)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;14)</td><td char="&#177;" align="char">87.4&#8201;&#177;&#8201;6.3</td><td char="(" align="char">(75.0&#8211;99.7)</td><td char="." align="char">0.074</td></tr><tr><td colspan="4">A5.1</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;19)</td><td char="&#177;" align="char">65.2&#8201;&#177;&#8201;9.8</td><td char="(" align="char">(45.9&#8211;84.5)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">75.2&#8201;&#177;&#8201;5.7</td><td char="(" align="char">(63.9&#8211;86.6)</td><td char="." align="char">0.257</td></tr><tr><td colspan="4">A9</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;48)</td><td char="&#177;" align="char">75.9&#8201;&#177;&#8201;5.5</td><td char="(" align="char">(65.0&#8211;86.8)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;13)</td><td char="&#177;" align="char">59.5&#8201;&#177;&#8201;10.6</td><td char="(" align="char">(38.7&#8211;80.3)</td><td char="." align="char">0.106</td></tr><tr><td colspan="4">CA24</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">66.7&#8201;&#177;&#8201;6.1</td><td char="(" align="char">(54.7&#8211;78.7)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;19)</td><td char="&#177;" align="char">84.3&#8201;&#177;&#8201;8.6</td><td char="(" align="char">(67.4&#8211;101.3)</td><td char="." align="char">0.108</td></tr><tr><td colspan="4">Microsatellite instability (&#8805;1 marker)</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;54)</td><td char="&#177;" align="char">71.7&#8201;&#177;&#8201;5.7</td><td char="(" align="char">(60.4&#8211;83.0)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;7)</td><td char="&#177;" align="char">82.2&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(63.6&#8211;100.9)</td><td char="." align="char">0.410</td></tr><tr><td colspan="4"><italic>KRAS</italic> codon 12 mutations</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;44)</td><td char="&#177;" align="char">78.7&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(66.9&#8211;90.4)</td><td/></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;17)</td><td char="&#177;" align="char">58.7&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(40.0&#8211;77.5)</td><td char="." align="char">0.093</td></tr></tbody></table><table-wrap-foot><p textid="45">Univariate analysis of tumor-related survival times of patients with indicated clinicopathological parameters and selected MICA-TM (A4, A5, A5.1, A9) and MICB C1_2_A (CA24) alleles in patients with colorectal cancer (<italic>n</italic>&#8201;=&#8201;61). Kaplan&#8211;Meier analysis and the log rank test were used for comparisons and statistical evaluation</p></table-wrap-foot></table-wrap>
###xml 2611 2617 2561 2567 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 2807 2827 2757 2777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Short vertical lines</italic>
###xml 2895 2896 2845 2846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2931 2932 2881 2882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2939 2940 2889 2890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2617 2949 2567 2899 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Survival analysis in relation to MICA-TM A4 allele haplotype. Kaplan&#8211;Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with colorectal cancer. <italic>Short vertical lines</italic> indicate censored observations for comparison of patients without (<italic>n</italic>&#8201;=&#8201;46) and with MICA-TM A4 allele (<italic>n</italic>&#8201;=&#8201;15, <italic>p</italic>&#8201;=&#8201;0.015)</p>
###xml 2617 2949 2567 2899 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">Survival analysis in relation to MICA-TM A4 allele haplotype. Kaplan&#8211;Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with colorectal cancer. <italic>Short vertical lines</italic> indicate censored observations for comparison of patients without (<italic>n</italic>&#8201;=&#8201;46) and with MICA-TM A4 allele (<italic>n</italic>&#8201;=&#8201;15, <italic>p</italic>&#8201;=&#8201;0.015)</p></caption>
###xml 2949 2949 2899 2899 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10875_2009_9288_Fig1_HTML" id="MO1"/>
###xml 2611 2949 2561 2899 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="46">Survival analysis in relation to MICA-TM A4 allele haplotype. Kaplan&#8211;Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with colorectal cancer. <italic>Short vertical lines</italic> indicate censored observations for comparison of patients without (<italic>n</italic>&#8201;=&#8201;46) and with MICA-TM A4 allele (<italic>n</italic>&#8201;=&#8201;15, <italic>p</italic>&#8201;=&#8201;0.015)</p></caption><graphic position="anchor" xlink:href="10875_2009_9288_Fig1_HTML" id="MO1"/></fig>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 688 696 <span type="species:ncbi:9606">patients</span>
###xml 882 890 <span type="species:ncbi:9606">patients</span>
###xml 2344 2352 <span type="species:ncbi:9606">patients</span>
###xml 2473 2481 <span type="species:ncbi:9606">patients</span>
###xml 2774 2782 <span type="species:ncbi:9606">patients</span>
###xml 2877 2885 <span type="species:ncbi:9606">patients</span>
Overall survival was analyzed in 61 patients with sporadic colorectal carcinomas, followed and documented prospectively in an institutional data base. Tumor-related postoperative survival was 86.0 +/- 4.4 months for patients following complete tumor resection (R0-status; n = 45) and 29.8 +/- 8.4 months for patients with tumor infiltrated resection margins or remaining distant metastasis (n = 25; p < 0.001). Survival in the study cohort was related to classical parameters of tumor progression like lymph node involvement (p = 0.005) and UICC stages (p = 0.001) according to univariate analysis, as shown in Table IV. Further analysis indicated significantly shorter survival times in patients positive for the MICA-TM A4 allele (negative vs positive, 80.6 vs 51.9 months; p = 0.015, Fig. 1). Estimated 5-year survival times were 75% and 43% for MICA-TM A4 negative and positive patients, respectively. Multivariate analysis using the Cox regression model after exclusion of the variable metastatic disease indicated that presence of MICA-TM A4 allele (HR, 2.71; 95% CI, 1.13-6.49; p = 0.025) and the tumor-related nodal status (HR, 3.99; 95% CI, 1.61-9.86; p = 0.003) were independent prognostic variables. Table IVSurvival of Colorectal Cancer PatientsTumor-related parametersSurvival times (mean +/- SD; months)(95% Confidence interval)p valueTumor invasion T1/2 (n = 13)85.0 +/- 9.6(66.2-103.9)0.113 T3/4 (n = 48)69.0 +/- 6.0(57.1-80.8)Lymph node involvement N0 (n = 34)88.8 +/- 5.4(78.1-99.4)0.005 N1 (n = 18)65.3 +/- 8.9(47.7-82.8) N2 (n = 9)25.9 +/- 5.2(6.9-44.9)UICC stages UICC I/II (n = 30)93.9 +/- 4.8(84.4-103.4) UICC III/IV (n = 31)52.7 +/- 7.3(38.3-67.0)<0.001A4 No (n = 47)80.6 +/- 5.6(69.7-91.6) Yes (n = 14)51.9 +/- 10.9(30.5-73.2)0.015A5 No (n = 47)56.0 +/- 6.1(56.0-80.2) Yes (n = 14)87.4 +/- 6.3(75.0-99.7)0.074A5.1 No (n = 19)65.2 +/- 9.8(45.9-84.5) Yes (n = 42)75.2 +/- 5.7(63.9-86.6)0.257A9 No (n = 48)75.9 +/- 5.5(65.0-86.8) Yes (n = 13)59.5 +/- 10.6(38.7-80.3)0.106CA24 No (n = 42)66.7 +/- 6.1(54.7-78.7) Yes (n = 19)84.3 +/- 8.6(67.4-101.3)0.108Microsatellite instability (>/=1 marker) No (n = 54)71.7 +/- 5.7(60.4-83.0) Yes (n = 7)82.2 +/- 9.5(63.6-100.9)0.410KRAS codon 12 mutations No (n = 44)78.7 +/- 6.0(66.9-90.4) Yes (n = 17)58.7 +/- 9.5(40.0-77.5)0.093Univariate analysis of tumor-related survival times of patients with indicated clinicopathological parameters and selected MICA-TM (A4, A5, A5.1, A9) and MICB C1_2_A (CA24) alleles in patients with colorectal cancer (n = 61). Kaplan-Meier analysis and the log rank test were used for comparisons and statistical evaluationFig. 1Survival analysis in relation to MICA-TM A4 allele haplotype. Kaplan-Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with colorectal cancer. Short vertical lines indicate censored observations for comparison of patients without (n = 46) and with MICA-TM A4 allele (n = 15, p = 0.015)
###end p 43
###begin p 44
###xml 30 38 <span type="species:ncbi:9606">Patients</span>
Survival of Colorectal Cancer Patients
###end p 44
###begin p 45
###xml 217 218 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Univariate analysis of tumor-related survival times of patients with indicated clinicopathological parameters and selected MICA-TM (A4, A5, A5.1, A9) and MICB C1_2_A (CA24) alleles in patients with colorectal cancer (n = 61). Kaplan-Meier analysis and the log rank test were used for comparisons and statistical evaluation
###end p 45
###begin p 46
###xml 190 210 190 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Short vertical lines</italic>
###xml 278 279 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
Survival analysis in relation to MICA-TM A4 allele haplotype. Kaplan-Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with colorectal cancer. Short vertical lines indicate censored observations for comparison of patients without (n = 46) and with MICA-TM A4 allele (n = 15, p = 0.015)
###end p 46
###begin title 47
Survival Analysis in Microsatellite Stable Tumors
###end title 47
###begin p 48
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 339 340 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">IV</xref>
###xml 429 430 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 564 565 564 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 658 659 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab5" ref-type="table">V</xref>
###xml 870 871 870 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 873 874 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1192 1193 1192 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1257 1258 1257 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1329 1330 1329 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1439 1445 1439 1445 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1676 1690 1676 1690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vertical lines</italic>
###xml 1758 1759 1758 1759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1794 1795 1794 1795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1802 1803 1802 1803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1445 1877 1445 1877 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49">MICA-TM A4 allele detection in microsatellite stable colorectal cancer patients. Kaplan&#8211;Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with microsatellite stable colorectal cancer. <italic>Vertical lines</italic> indicate censored observations for comparison of patients without (<italic>n</italic>&#8201;=&#8201;42) and with MICA-TM A4 allele (<italic>n</italic>&#8201;=&#8201;12, <italic>p</italic>&#8201;=&#8201;0.006). The estimated 5-year survival rate was 72% vs 38%, respectively</p>
###xml 1445 1877 1445 1877 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49">MICA-TM A4 allele detection in microsatellite stable colorectal cancer patients. Kaplan&#8211;Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with microsatellite stable colorectal cancer. <italic>Vertical lines</italic> indicate censored observations for comparison of patients without (<italic>n</italic>&#8201;=&#8201;42) and with MICA-TM A4 allele (<italic>n</italic>&#8201;=&#8201;12, <italic>p</italic>&#8201;=&#8201;0.006). The estimated 5-year survival rate was 72% vs 38%, respectively</p></caption>
###xml 1877 1877 1877 1877 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10875_2009_9288_Fig2_HTML" id="MO2"/>
###xml 1439 1877 1439 1877 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="49">MICA-TM A4 allele detection in microsatellite stable colorectal cancer patients. Kaplan&#8211;Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with microsatellite stable colorectal cancer. <italic>Vertical lines</italic> indicate censored observations for comparison of patients without (<italic>n</italic>&#8201;=&#8201;42) and with MICA-TM A4 allele (<italic>n</italic>&#8201;=&#8201;12, <italic>p</italic>&#8201;=&#8201;0.006). The estimated 5-year survival rate was 72% vs 38%, respectively</p></caption><graphic position="anchor" xlink:href="10875_2009_9288_Fig2_HTML" id="MO2"/></fig>
###xml 1877 1884 1877 1884 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table V</label>
###xml 1884 1949 1884 1949 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50">Survival of Patients with Microsatellite Stable Colorectal Cancer</p>
###xml 1884 1949 1884 1949 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="50">Survival of Patients with Microsatellite Stable Colorectal Cancer</p></caption>
###xml 1949 1973 1949 1973 <th xmlns:xlink="http://www.w3.org/1999/xlink">Tumor-related parameters</th>
###xml 1973 2009 1973 2007 <th xmlns:xlink="http://www.w3.org/1999/xlink">Survival times (mean &#177; SD; months)</th>
###xml 2009 2034 2007 2032 <th xmlns:xlink="http://www.w3.org/1999/xlink">(95% Confidence interval)</th>
###xml 2034 2035 2032 2033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2034 2041 2032 2039 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 1949 2041 1949 2039 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Tumor-related parameters</th><th>Survival times (mean &#177; SD; months)</th><th>(95% Confidence interval)</th><th><italic>p</italic> value</th></tr>
###xml 1949 2041 1949 2039 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Tumor-related parameters</th><th>Survival times (mean &#177; SD; months)</th><th>(95% Confidence interval)</th><th><italic>p</italic> value</th></tr></thead>
###xml 2041 2055 2039 2053 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Tumor invasion</td>
###xml 2041 2055 2039 2053 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Tumor invasion</td></tr>
###xml 2062 2063 2060 2061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2055 2069 2053 2067 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;12)</td>
###xml 2069 2082 2067 2078 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">81.8&#8201;&#177;&#8201;11.4</td>
###xml 2082 2094 2078 2090 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(59.5&#8211;104.2)</td>
###xml 2094 2099 2090 2095 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">0.209</td>
###xml 2055 2099 2053 2095 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">81.8&#8201;&#177;&#8201;11.4</td><td char="(" align="char">(59.5&#8211;104.2)</td><td char="." align="char" rowspan="2">0.209</td></tr>
###xml 2106 2107 2102 2103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2099 2113 2095 2109 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;42)</td>
###xml 2113 2125 2109 2119 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">67.4&#8201;&#177;&#8201;5.8</td>
###xml 2125 2136 2119 2130 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(54.5&#8211;80.3)</td>
###xml 2099 2136 2095 2130 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">67.4&#8201;&#177;&#8201;5.8</td><td char="(" align="char">(54.5&#8211;80.3)</td></tr>
###xml 2136 2158 2130 2152 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Lymph node involvement</td>
###xml 2136 2158 2130 2152 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Lymph node involvement</td></tr>
###xml 2171 2172 2165 2166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2158 2178 2152 2172 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;N negative (<italic>n</italic>&#8201;=&#8201;28)</td>
###xml 2178 2190 2172 2182 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">89.9&#8201;&#177;&#8201;6.0</td>
###xml 2190 2202 2182 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(78.1&#8211;101.7)</td>
###xml 2202 2207 2194 2199 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">0.001</td>
###xml 2158 2207 2152 2199 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;N negative (<italic>n</italic>&#8201;=&#8201;28)</td><td char="&#177;" align="char">89.9&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(78.1&#8211;101.7)</td><td char="." align="char" rowspan="2">0.001</td></tr>
###xml 2220 2221 2212 2213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2207 2227 2199 2219 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;N positive (<italic>n</italic>&#8201;=&#8201;26)</td>
###xml 2227 2239 2219 2229 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">48.6&#8201;&#177;&#8201;7.9</td>
###xml 2239 2250 2229 2240 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(33.1&#8211;64.1)</td>
###xml 2207 2250 2199 2240 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;N positive (<italic>n</italic>&#8201;=&#8201;26)</td><td char="&#177;" align="char">48.6&#8201;&#177;&#8201;7.9</td><td char="(" align="char">(33.1&#8211;64.1)</td></tr>
###xml 2250 2261 2240 2251 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">UICC stages</td>
###xml 2250 2261 2240 2251 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">UICC stages</td></tr>
###xml 2273 2274 2263 2264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2261 2280 2251 2270 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;24)</td>
###xml 2280 2292 2270 2280 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">96.7&#8201;&#177;&#8201;4.9</td>
###xml 2292 2304 2280 2292 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(87.0&#8211;106.4)</td>
###xml 2304 2310 2292 2298 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">&lt;0.001</td>
###xml 2261 2310 2251 2298 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;24)</td><td char="&#177;" align="char">96.7&#8201;&#177;&#8201;4.9</td><td char="(" align="char">(87.0&#8211;106.4)</td><td char="." align="char" rowspan="2">&lt;0.001</td></tr>
###xml 2324 2325 2312 2313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2310 2331 2298 2319 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;30)</td>
###xml 2331 2343 2319 2329 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">50.8&#8201;&#177;&#8201;7.3</td>
###xml 2343 2355 2329 2341 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(36.4&#8211;65.23)</td>
###xml 2310 2355 2298 2341 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;30)</td><td char="&#177;" align="char">50.8&#8201;&#177;&#8201;7.3</td><td char="(" align="char">(36.4&#8211;65.23)</td></tr>
###xml 2355 2373 2341 2359 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">Distant metastasis</td>
###xml 2355 2373 2341 2359 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">Distant metastasis</td></tr>
###xml 2378 2379 2364 2365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2373 2385 2359 2371 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;M0 (<italic>n</italic>&#8201;=&#8201;38)</td>
###xml 2385 2397 2371 2381 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">86.7&#8201;&#177;&#8201;5.4</td>
###xml 2397 2408 2381 2392 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(76.0&#8211;97.4)</td>
###xml 2408 2414 2392 2398 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">&lt;0.001</td>
###xml 2373 2414 2359 2398 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;M0 (<italic>n</italic>&#8201;=&#8201;38)</td><td char="&#177;" align="char">86.7&#8201;&#177;&#8201;5.4</td><td char="(" align="char">(76.0&#8211;97.4)</td><td char="." align="char" rowspan="2">&lt;0.001</td></tr>
###xml 2419 2420 2403 2404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2414 2426 2398 2410 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;M1 (<italic>n</italic>&#8201;=&#8201;16)</td>
###xml 2426 2438 2410 2420 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">38.0&#8201;&#177;&#8201;9.5</td>
###xml 2438 2449 2420 2431 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(19.4&#8211;65.7)</td>
###xml 2414 2449 2398 2431 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;M1 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="&#177;" align="char">38.0&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(19.4&#8211;65.7)</td></tr>
###xml 2449 2451 2431 2433 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">A4</td>
###xml 2449 2451 2431 2433 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">A4</td></tr>
###xml 2456 2457 2438 2439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2451 2463 2433 2445 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td>
###xml 2463 2475 2445 2455 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">79.1&#8201;&#177;&#8201;6.0</td>
###xml 2475 2486 2455 2466 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(67.2&#8211;91.0)</td>
###xml 2486 2491 2466 2471 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">0.006</td>
###xml 2451 2491 2433 2471 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">79.1&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(67.2&#8211;91.0)</td><td char="." align="char" rowspan="2">0.006</td></tr>
###xml 2497 2498 2477 2478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2491 2504 2471 2484 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td>
###xml 2504 2517 2484 2495 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">46.4&#8201;&#177;&#8201;12.1</td>
###xml 2517 2528 2495 2506 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(22.5&#8211;70.3)</td>
###xml 2491 2528 2471 2506 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">46.4&#8201;&#177;&#8201;12.1</td><td char="(" align="char">(22.5&#8211;70.3)</td></tr>
###xml 2528 2530 2506 2508 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">A5</td>
###xml 2528 2530 2506 2508 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">A5</td></tr>
###xml 2535 2536 2513 2514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2530 2542 2508 2520 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td>
###xml 2542 2554 2520 2530 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">65.3&#8201;&#177;&#8201;6.6</td>
###xml 2554 2565 2530 2541 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(52.4&#8211;78.3)</td>
###xml 2565 2570 2541 2546 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">0.042</td>
###xml 2530 2570 2508 2546 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">65.3&#8201;&#177;&#8201;6.6</td><td char="(" align="char">(52.4&#8211;78.3)</td><td char="." align="char" rowspan="2">0.042</td></tr>
###xml 2576 2577 2552 2553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2570 2583 2546 2559 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td>
###xml 2583 2595 2559 2569 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">88.4&#8201;&#177;&#8201;7.1</td>
###xml 2595 2607 2569 2581 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(74.3&#8211;102.5)</td>
###xml 2570 2607 2546 2581 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">88.4&#8201;&#177;&#8201;7.1</td><td char="(" align="char">(74.3&#8211;102.5)</td></tr>
###xml 2607 2611 2581 2585 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">A5.1</td>
###xml 2607 2611 2581 2585 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">A5.1</td></tr>
###xml 2616 2617 2590 2591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2611 2623 2585 2597 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;16)</td>
###xml 2623 2637 2597 2609 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">62.7&#8201;&#177;&#8201;10.89</td>
###xml 2637 2648 2609 2620 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(41.4&#8211;84.1)</td>
###xml 2648 2653 2620 2625 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">0.236</td>
###xml 2611 2653 2585 2625 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;16)</td><td char="&#177;" align="char">62.7&#8201;&#177;&#8201;10.89</td><td char="(" align="char">(41.4&#8211;84.1)</td><td char="." align="char" rowspan="2">0.236</td></tr>
###xml 2659 2660 2631 2632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2653 2666 2625 2638 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;38)</td>
###xml 2666 2678 2638 2648 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">73.3&#8201;&#177;&#8201;6.3</td>
###xml 2678 2689 2648 2659 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(60.9&#8211;85.8)</td>
###xml 2653 2689 2625 2659 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;38)</td><td char="&#177;" align="char">73.3&#8201;&#177;&#8201;6.3</td><td char="(" align="char">(60.9&#8211;85.8)</td></tr>
###xml 2689 2691 2659 2661 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">A9</td>
###xml 2689 2691 2659 2661 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">A9</td></tr>
###xml 2696 2697 2666 2667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2691 2703 2661 2673 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;43)</td>
###xml 2703 2715 2673 2683 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">75.7&#8201;&#177;&#8201;6.0</td>
###xml 2715 2726 2683 2694 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(63.8&#8211;87.6)</td>
###xml 2726 2731 2694 2699 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">0.034</td>
###xml 2691 2731 2661 2699 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;43)</td><td char="&#177;" align="char">75.7&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(63.8&#8211;87.6)</td><td char="." align="char" rowspan="2">0.034</td></tr>
###xml 2737 2738 2705 2706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2731 2744 2699 2712 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td>
###xml 2744 2757 2712 2723 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">51.4&#8201;&#177;&#8201;10.9</td>
###xml 2757 2768 2723 2734 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(30.0&#8211;72.8)</td>
###xml 2731 2768 2699 2734 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td><td char="&#177;" align="char">51.4&#8201;&#177;&#8201;10.9</td><td char="(" align="char">(30.0&#8211;72.8)</td></tr>
###xml 2768 2772 2734 2738 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">CA24</td>
###xml 2768 2772 2734 2738 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4">CA24</td></tr>
###xml 2777 2778 2743 2744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2772 2784 2738 2750 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;37)</td>
###xml 2784 2796 2750 2760 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">64.8&#8201;&#177;&#8201;6.6</td>
###xml 2796 2807 2760 2771 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(51.7&#8211;77.9)</td>
###xml 2807 2812 2771 2776 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">0.156</td>
###xml 2772 2812 2738 2776 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;37)</td><td char="&#177;" align="char">64.8&#8201;&#177;&#8201;6.6</td><td char="(" align="char">(51.7&#8211;77.9)</td><td char="." align="char" rowspan="2">0.156</td></tr>
###xml 2818 2819 2782 2783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2812 2825 2776 2789 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td>
###xml 2825 2837 2789 2799 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">81.9&#8201;&#177;&#8201;9.5</td>
###xml 2837 2849 2799 2811 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(63.2&#8211;100.6)</td>
###xml 2812 2849 2776 2811 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td><td char="&#177;" align="char">81.9&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(63.2&#8211;100.6)</td></tr>
###xml 2849 2853 2811 2815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 2849 2872 2811 2834 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4"><italic>KRAS</italic> codon 12 mutations</td>
###xml 2849 2872 2811 2834 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="4"><italic>KRAS</italic> codon 12 mutations</td></tr>
###xml 2877 2878 2839 2840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2872 2884 2834 2846 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No (<italic>n</italic>&#8201;=&#8201;39)</td>
###xml 2884 2896 2846 2856 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">77.2&#8201;&#177;&#8201;6.5</td>
###xml 2896 2907 2856 2867 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(64.4&#8211;90.0)</td>
###xml 2907 2912 2867 2872 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" rowspan="2">0.121</td>
###xml 2872 2912 2834 2872 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No (<italic>n</italic>&#8201;=&#8201;39)</td><td char="&#177;" align="char">77.2&#8201;&#177;&#8201;6.5</td><td char="(" align="char">(64.4&#8211;90.0)</td><td char="." align="char" rowspan="2">0.121</td></tr>
###xml 2918 2919 2878 2879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2912 2925 2872 2885 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Yes (<italic>n</italic>&#8201;=&#8201;15)</td>
###xml 2925 2938 2885 2896 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">54.5&#8201;&#177;&#8201;10.5</td>
###xml 2938 2949 2896 2907 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">(33.9&#8211;75.1)</td>
###xml 2912 2949 2872 2907 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;15)</td><td char="&#177;" align="char">54.5&#8201;&#177;&#8201;10.5</td><td char="(" align="char">(33.9&#8211;75.1)</td></tr>
###xml 2041 2949 2039 2907 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="4">Tumor invasion</td></tr><tr><td>&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">81.8&#8201;&#177;&#8201;11.4</td><td char="(" align="char">(59.5&#8211;104.2)</td><td char="." align="char" rowspan="2">0.209</td></tr><tr><td>&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">67.4&#8201;&#177;&#8201;5.8</td><td char="(" align="char">(54.5&#8211;80.3)</td></tr><tr><td colspan="4">Lymph node involvement</td></tr><tr><td>&#160;N negative (<italic>n</italic>&#8201;=&#8201;28)</td><td char="&#177;" align="char">89.9&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(78.1&#8211;101.7)</td><td char="." align="char" rowspan="2">0.001</td></tr><tr><td>&#160;N positive (<italic>n</italic>&#8201;=&#8201;26)</td><td char="&#177;" align="char">48.6&#8201;&#177;&#8201;7.9</td><td char="(" align="char">(33.1&#8211;64.1)</td></tr><tr><td colspan="4">UICC stages</td></tr><tr><td>&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;24)</td><td char="&#177;" align="char">96.7&#8201;&#177;&#8201;4.9</td><td char="(" align="char">(87.0&#8211;106.4)</td><td char="." align="char" rowspan="2">&lt;0.001</td></tr><tr><td>&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;30)</td><td char="&#177;" align="char">50.8&#8201;&#177;&#8201;7.3</td><td char="(" align="char">(36.4&#8211;65.23)</td></tr><tr><td colspan="4">Distant metastasis</td></tr><tr><td>&#160;M0 (<italic>n</italic>&#8201;=&#8201;38)</td><td char="&#177;" align="char">86.7&#8201;&#177;&#8201;5.4</td><td char="(" align="char">(76.0&#8211;97.4)</td><td char="." align="char" rowspan="2">&lt;0.001</td></tr><tr><td>&#160;M1 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="&#177;" align="char">38.0&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(19.4&#8211;65.7)</td></tr><tr><td colspan="4">A4</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">79.1&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(67.2&#8211;91.0)</td><td char="." align="char" rowspan="2">0.006</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">46.4&#8201;&#177;&#8201;12.1</td><td char="(" align="char">(22.5&#8211;70.3)</td></tr><tr><td colspan="4">A5</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">65.3&#8201;&#177;&#8201;6.6</td><td char="(" align="char">(52.4&#8211;78.3)</td><td char="." align="char" rowspan="2">0.042</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">88.4&#8201;&#177;&#8201;7.1</td><td char="(" align="char">(74.3&#8211;102.5)</td></tr><tr><td colspan="4">A5.1</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;16)</td><td char="&#177;" align="char">62.7&#8201;&#177;&#8201;10.89</td><td char="(" align="char">(41.4&#8211;84.1)</td><td char="." align="char" rowspan="2">0.236</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;38)</td><td char="&#177;" align="char">73.3&#8201;&#177;&#8201;6.3</td><td char="(" align="char">(60.9&#8211;85.8)</td></tr><tr><td colspan="4">A9</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;43)</td><td char="&#177;" align="char">75.7&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(63.8&#8211;87.6)</td><td char="." align="char" rowspan="2">0.034</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td><td char="&#177;" align="char">51.4&#8201;&#177;&#8201;10.9</td><td char="(" align="char">(30.0&#8211;72.8)</td></tr><tr><td colspan="4">CA24</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;37)</td><td char="&#177;" align="char">64.8&#8201;&#177;&#8201;6.6</td><td char="(" align="char">(51.7&#8211;77.9)</td><td char="." align="char" rowspan="2">0.156</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td><td char="&#177;" align="char">81.9&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(63.2&#8211;100.6)</td></tr><tr><td colspan="4"><italic>KRAS</italic> codon 12 mutations</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;39)</td><td char="&#177;" align="char">77.2&#8201;&#177;&#8201;6.5</td><td char="(" align="char">(64.4&#8211;90.0)</td><td char="." align="char" rowspan="2">0.121</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;15)</td><td char="&#177;" align="char">54.5&#8201;&#177;&#8201;10.5</td><td char="(" align="char">(33.9&#8211;75.1)</td></tr></tbody>
###xml 1949 2949 1949 2907 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Tumor-related parameters</th><th>Survival times (mean &#177; SD; months)</th><th>(95% Confidence interval)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Tumor invasion</td></tr><tr><td>&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">81.8&#8201;&#177;&#8201;11.4</td><td char="(" align="char">(59.5&#8211;104.2)</td><td char="." align="char" rowspan="2">0.209</td></tr><tr><td>&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">67.4&#8201;&#177;&#8201;5.8</td><td char="(" align="char">(54.5&#8211;80.3)</td></tr><tr><td colspan="4">Lymph node involvement</td></tr><tr><td>&#160;N negative (<italic>n</italic>&#8201;=&#8201;28)</td><td char="&#177;" align="char">89.9&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(78.1&#8211;101.7)</td><td char="." align="char" rowspan="2">0.001</td></tr><tr><td>&#160;N positive (<italic>n</italic>&#8201;=&#8201;26)</td><td char="&#177;" align="char">48.6&#8201;&#177;&#8201;7.9</td><td char="(" align="char">(33.1&#8211;64.1)</td></tr><tr><td colspan="4">UICC stages</td></tr><tr><td>&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;24)</td><td char="&#177;" align="char">96.7&#8201;&#177;&#8201;4.9</td><td char="(" align="char">(87.0&#8211;106.4)</td><td char="." align="char" rowspan="2">&lt;0.001</td></tr><tr><td>&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;30)</td><td char="&#177;" align="char">50.8&#8201;&#177;&#8201;7.3</td><td char="(" align="char">(36.4&#8211;65.23)</td></tr><tr><td colspan="4">Distant metastasis</td></tr><tr><td>&#160;M0 (<italic>n</italic>&#8201;=&#8201;38)</td><td char="&#177;" align="char">86.7&#8201;&#177;&#8201;5.4</td><td char="(" align="char">(76.0&#8211;97.4)</td><td char="." align="char" rowspan="2">&lt;0.001</td></tr><tr><td>&#160;M1 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="&#177;" align="char">38.0&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(19.4&#8211;65.7)</td></tr><tr><td colspan="4">A4</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">79.1&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(67.2&#8211;91.0)</td><td char="." align="char" rowspan="2">0.006</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">46.4&#8201;&#177;&#8201;12.1</td><td char="(" align="char">(22.5&#8211;70.3)</td></tr><tr><td colspan="4">A5</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">65.3&#8201;&#177;&#8201;6.6</td><td char="(" align="char">(52.4&#8211;78.3)</td><td char="." align="char" rowspan="2">0.042</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">88.4&#8201;&#177;&#8201;7.1</td><td char="(" align="char">(74.3&#8211;102.5)</td></tr><tr><td colspan="4">A5.1</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;16)</td><td char="&#177;" align="char">62.7&#8201;&#177;&#8201;10.89</td><td char="(" align="char">(41.4&#8211;84.1)</td><td char="." align="char" rowspan="2">0.236</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;38)</td><td char="&#177;" align="char">73.3&#8201;&#177;&#8201;6.3</td><td char="(" align="char">(60.9&#8211;85.8)</td></tr><tr><td colspan="4">A9</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;43)</td><td char="&#177;" align="char">75.7&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(63.8&#8211;87.6)</td><td char="." align="char" rowspan="2">0.034</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td><td char="&#177;" align="char">51.4&#8201;&#177;&#8201;10.9</td><td char="(" align="char">(30.0&#8211;72.8)</td></tr><tr><td colspan="4">CA24</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;37)</td><td char="&#177;" align="char">64.8&#8201;&#177;&#8201;6.6</td><td char="(" align="char">(51.7&#8211;77.9)</td><td char="." align="char" rowspan="2">0.156</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td><td char="&#177;" align="char">81.9&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(63.2&#8211;100.6)</td></tr><tr><td colspan="4"><italic>KRAS</italic> codon 12 mutations</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;39)</td><td char="&#177;" align="char">77.2&#8201;&#177;&#8201;6.5</td><td char="(" align="char">(64.4&#8211;90.0)</td><td char="." align="char" rowspan="2">0.121</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;15)</td><td char="&#177;" align="char">54.5&#8201;&#177;&#8201;10.5</td><td char="(" align="char">(33.9&#8211;75.1)</td></tr></tbody></table>
###xml 3206 3207 3164 3165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2949 3311 2907 3269 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">Univariate analysis of tumor-related survival times of patients with microsatellite stable (MIN negative) colorectal cancer and selected MICA-TM (A4, A5, A5,1, A9) and MICB C1_2_A (CA24) alleles in association with indicated clinicopathological parameters (<italic>n</italic>&#8201;=&#8201;54). Kaplan&#8211;Meier analysis and the log rank test were used for comparisons and statistical evaluation</p>
###xml 2949 3311 2907 3269 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51">Univariate analysis of tumor-related survival times of patients with microsatellite stable (MIN negative) colorectal cancer and selected MICA-TM (A4, A5, A5,1, A9) and MICB C1_2_A (CA24) alleles in association with indicated clinicopathological parameters (<italic>n</italic>&#8201;=&#8201;54). Kaplan&#8211;Meier analysis and the log rank test were used for comparisons and statistical evaluation</p></table-wrap-foot>
###xml 1877 3311 1877 3269 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab5"><label>Table V</label><caption><p textid="50">Survival of Patients with Microsatellite Stable Colorectal Cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Tumor-related parameters</th><th>Survival times (mean &#177; SD; months)</th><th>(95% Confidence interval)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Tumor invasion</td></tr><tr><td>&#160;T1/2 (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">81.8&#8201;&#177;&#8201;11.4</td><td char="(" align="char">(59.5&#8211;104.2)</td><td char="." align="char" rowspan="2">0.209</td></tr><tr><td>&#160;T3/4 (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">67.4&#8201;&#177;&#8201;5.8</td><td char="(" align="char">(54.5&#8211;80.3)</td></tr><tr><td colspan="4">Lymph node involvement</td></tr><tr><td>&#160;N negative (<italic>n</italic>&#8201;=&#8201;28)</td><td char="&#177;" align="char">89.9&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(78.1&#8211;101.7)</td><td char="." align="char" rowspan="2">0.001</td></tr><tr><td>&#160;N positive (<italic>n</italic>&#8201;=&#8201;26)</td><td char="&#177;" align="char">48.6&#8201;&#177;&#8201;7.9</td><td char="(" align="char">(33.1&#8211;64.1)</td></tr><tr><td colspan="4">UICC stages</td></tr><tr><td>&#160;UICC I/II (<italic>n</italic>&#8201;=&#8201;24)</td><td char="&#177;" align="char">96.7&#8201;&#177;&#8201;4.9</td><td char="(" align="char">(87.0&#8211;106.4)</td><td char="." align="char" rowspan="2">&lt;0.001</td></tr><tr><td>&#160;UICC III/IV (<italic>n</italic>&#8201;=&#8201;30)</td><td char="&#177;" align="char">50.8&#8201;&#177;&#8201;7.3</td><td char="(" align="char">(36.4&#8211;65.23)</td></tr><tr><td colspan="4">Distant metastasis</td></tr><tr><td>&#160;M0 (<italic>n</italic>&#8201;=&#8201;38)</td><td char="&#177;" align="char">86.7&#8201;&#177;&#8201;5.4</td><td char="(" align="char">(76.0&#8211;97.4)</td><td char="." align="char" rowspan="2">&lt;0.001</td></tr><tr><td>&#160;M1 (<italic>n</italic>&#8201;=&#8201;16)</td><td char="&#177;" align="char">38.0&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(19.4&#8211;65.7)</td></tr><tr><td colspan="4">A4</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">79.1&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(67.2&#8211;91.0)</td><td char="." align="char" rowspan="2">0.006</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">46.4&#8201;&#177;&#8201;12.1</td><td char="(" align="char">(22.5&#8211;70.3)</td></tr><tr><td colspan="4">A5</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;42)</td><td char="&#177;" align="char">65.3&#8201;&#177;&#8201;6.6</td><td char="(" align="char">(52.4&#8211;78.3)</td><td char="." align="char" rowspan="2">0.042</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;12)</td><td char="&#177;" align="char">88.4&#8201;&#177;&#8201;7.1</td><td char="(" align="char">(74.3&#8211;102.5)</td></tr><tr><td colspan="4">A5.1</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;16)</td><td char="&#177;" align="char">62.7&#8201;&#177;&#8201;10.89</td><td char="(" align="char">(41.4&#8211;84.1)</td><td char="." align="char" rowspan="2">0.236</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;38)</td><td char="&#177;" align="char">73.3&#8201;&#177;&#8201;6.3</td><td char="(" align="char">(60.9&#8211;85.8)</td></tr><tr><td colspan="4">A9</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;43)</td><td char="&#177;" align="char">75.7&#8201;&#177;&#8201;6.0</td><td char="(" align="char">(63.8&#8211;87.6)</td><td char="." align="char" rowspan="2">0.034</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td><td char="&#177;" align="char">51.4&#8201;&#177;&#8201;10.9</td><td char="(" align="char">(30.0&#8211;72.8)</td></tr><tr><td colspan="4">CA24</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;37)</td><td char="&#177;" align="char">64.8&#8201;&#177;&#8201;6.6</td><td char="(" align="char">(51.7&#8211;77.9)</td><td char="." align="char" rowspan="2">0.156</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;11)</td><td char="&#177;" align="char">81.9&#8201;&#177;&#8201;9.5</td><td char="(" align="char">(63.2&#8211;100.6)</td></tr><tr><td colspan="4"><italic>KRAS</italic> codon 12 mutations</td></tr><tr><td>&#160;No (<italic>n</italic>&#8201;=&#8201;39)</td><td char="&#177;" align="char">77.2&#8201;&#177;&#8201;6.5</td><td char="(" align="char">(64.4&#8211;90.0)</td><td char="." align="char" rowspan="2">0.121</td></tr><tr><td>&#160;Yes (<italic>n</italic>&#8201;=&#8201;15)</td><td char="&#177;" align="char">54.5&#8201;&#177;&#8201;10.5</td><td char="(" align="char">(33.9&#8211;75.1)</td></tr></tbody></table><table-wrap-foot><p textid="51">Univariate analysis of tumor-related survival times of patients with microsatellite stable (MIN negative) colorectal cancer and selected MICA-TM (A4, A5, A5,1, A9) and MICB C1_2_A (CA24) alleles in association with indicated clinicopathological parameters (<italic>n</italic>&#8201;=&#8201;54). Kaplan&#8211;Meier analysis and the log rank test were used for comparisons and statistical evaluation</p></table-wrap-foot></table-wrap>
###xml 3311 3317 3269 3275 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 3554 3568 3512 3526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vertical lines</italic>
###xml 3673 3674 3631 3632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 3742 3743 3700 3701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 3750 3751 3708 3709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3317 3762 3275 3718 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">MICA-TM A4 or A9 haplotype in microsatellite stable colorectal cancer patients. Kaplan&#8211;Meier analysis of tumor-related survival times in association with MICA-TM A4 or A9 alleles in patients with microsatellite stable colorectal cancer. <italic>Vertical lines</italic> indicate censored observations for comparison of patients either positive for MICA-TM A4 or A9 alleles (<italic>n</italic>&#8201;=&#8201;23) in comparison to patients without MICA-TM A4 and A9 alleles (<italic>n</italic>&#8201;=&#8201;31, <italic>p</italic>&#8201;&#8804;&#8201;0.001)</p>
###xml 3317 3762 3275 3718 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52">MICA-TM A4 or A9 haplotype in microsatellite stable colorectal cancer patients. Kaplan&#8211;Meier analysis of tumor-related survival times in association with MICA-TM A4 or A9 alleles in patients with microsatellite stable colorectal cancer. <italic>Vertical lines</italic> indicate censored observations for comparison of patients either positive for MICA-TM A4 or A9 alleles (<italic>n</italic>&#8201;=&#8201;23) in comparison to patients without MICA-TM A4 and A9 alleles (<italic>n</italic>&#8201;=&#8201;31, <italic>p</italic>&#8201;&#8804;&#8201;0.001)</p></caption>
###xml 3762 3762 3718 3718 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10875_2009_9288_Fig3_HTML" id="MO3"/>
###xml 3311 3762 3269 3718 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="52">MICA-TM A4 or A9 haplotype in microsatellite stable colorectal cancer patients. Kaplan&#8211;Meier analysis of tumor-related survival times in association with MICA-TM A4 or A9 alleles in patients with microsatellite stable colorectal cancer. <italic>Vertical lines</italic> indicate censored observations for comparison of patients either positive for MICA-TM A4 or A9 alleles (<italic>n</italic>&#8201;=&#8201;23) in comparison to patients without MICA-TM A4 and A9 alleles (<italic>n</italic>&#8201;=&#8201;31, <italic>p</italic>&#8201;&#8804;&#8201;0.001)</p></caption><graphic position="anchor" xlink:href="10875_2009_9288_Fig3_HTML" id="MO3"/></fig>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 483 491 <span type="species:ncbi:9606">patients</span>
###xml 709 717 <span type="species:ncbi:9606">patients</span>
###xml 771 779 <span type="species:ncbi:9606">patients</span>
###xml 1384 1392 <span type="species:ncbi:9606">patients</span>
###xml 1516 1524 <span type="species:ncbi:9606">patients</span>
###xml 1621 1629 <span type="species:ncbi:9606">patients</span>
###xml 1740 1748 <span type="species:ncbi:9606">patients</span>
###xml 1896 1904 <span type="species:ncbi:9606">Patients</span>
###xml 3004 3012 <span type="species:ncbi:9606">patients</span>
###xml 3387 3395 <span type="species:ncbi:9606">patients</span>
###xml 3499 3507 <span type="species:ncbi:9606">patients</span>
###xml 3618 3626 <span type="species:ncbi:9606">patients</span>
###xml 3698 3706 <span type="species:ncbi:9606">patients</span>
We have further analyzed survival times in patients with microsatellite stable tumors (n = 54). As shown in Fig. 2, prognostic relevance of MICA-TM A4 was even more evident in microsatellite stable tumors (p = 0.006) in comparison to the other known prognostic variables such as lymph node involvement (p = 0.001) and UICC classification (p < 0.001, Table IV). In addition, MICA-TM A9 was associated with reduced survival times (p = 0.034) in microsatellite stable colorectal cancer patients, while the MICA-TM A5 was inversely associated with a better prognosis (p = 0.042), providing evidence for a tumor suppressive effect of the MICA-TM A5 allele (Table V). Further combined analysis of colorectal cancer patients with MICA-TM alleles positive for either A4 or A9 vs patients negative for both A4 and A9 alleles had markedly reduced survival times, as shown in Fig. 3 (p < 0.001), with an estimated 5-year survival of 36% vs 85%, respectively. Multivariate analysis by Cox regression with inclusion of the variables MICA-TM A4, A5, A9, lymph node involvement, UICC stages, metastatic disease, and MICA-TM A4 or A9 positive indicated that metastatic disease (HR, 4.43; 95% CI, 1.66-11.81; p = 0.003), lymph node involvement (HR, 3.27; 95% CI, 1.14-9.30; p = 0.026) and MICA-TM A4 or A9 positive (HR, 4.02; 95% CI, 1.29-12.56; p = 0.016) were of independent prognostic relevance in patients with microsatellite stable colorectal tumors. Fig. 2MICA-TM A4 allele detection in microsatellite stable colorectal cancer patients. Kaplan-Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with microsatellite stable colorectal cancer. Vertical lines indicate censored observations for comparison of patients without (n = 42) and with MICA-TM A4 allele (n = 12, p = 0.006). The estimated 5-year survival rate was 72% vs 38%, respectivelyTable VSurvival of Patients with Microsatellite Stable Colorectal CancerTumor-related parametersSurvival times (mean +/- SD; months)(95% Confidence interval)p valueTumor invasion T1/2 (n = 12)81.8 +/- 11.4(59.5-104.2)0.209 T3/4 (n = 42)67.4 +/- 5.8(54.5-80.3)Lymph node involvement N negative (n = 28)89.9 +/- 6.0(78.1-101.7)0.001 N positive (n = 26)48.6 +/- 7.9(33.1-64.1)UICC stages UICC I/II (n = 24)96.7 +/- 4.9(87.0-106.4)<0.001 UICC III/IV (n = 30)50.8 +/- 7.3(36.4-65.23)Distant metastasis M0 (n = 38)86.7 +/- 5.4(76.0-97.4)<0.001 M1 (n = 16)38.0 +/- 9.5(19.4-65.7)A4 No (n = 42)79.1 +/- 6.0(67.2-91.0)0.006 Yes (n = 12)46.4 +/- 12.1(22.5-70.3)A5 No (n = 42)65.3 +/- 6.6(52.4-78.3)0.042 Yes (n = 12)88.4 +/- 7.1(74.3-102.5)A5.1 No (n = 16)62.7 +/- 10.89(41.4-84.1)0.236 Yes (n = 38)73.3 +/- 6.3(60.9-85.8)A9 No (n = 43)75.7 +/- 6.0(63.8-87.6)0.034 Yes (n = 11)51.4 +/- 10.9(30.0-72.8)CA24 No (n = 37)64.8 +/- 6.6(51.7-77.9)0.156 Yes (n = 11)81.9 +/- 9.5(63.2-100.6)KRAS codon 12 mutations No (n = 39)77.2 +/- 6.5(64.4-90.0)0.121 Yes (n = 15)54.5 +/- 10.5(33.9-75.1)Univariate analysis of tumor-related survival times of patients with microsatellite stable (MIN negative) colorectal cancer and selected MICA-TM (A4, A5, A5,1, A9) and MICB C1_2_A (CA24) alleles in association with indicated clinicopathological parameters (n = 54). Kaplan-Meier analysis and the log rank test were used for comparisons and statistical evaluationFig. 3MICA-TM A4 or A9 haplotype in microsatellite stable colorectal cancer patients. Kaplan-Meier analysis of tumor-related survival times in association with MICA-TM A4 or A9 alleles in patients with microsatellite stable colorectal cancer. Vertical lines indicate censored observations for comparison of patients either positive for MICA-TM A4 or A9 alleles (n = 23) in comparison to patients without MICA-TM A4 and A9 alleles (n = 31, p </= 0.001)
###end p 48
###begin p 49
###xml 231 245 231 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vertical lines</italic>
###xml 313 314 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 349 350 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 357 358 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
MICA-TM A4 allele detection in microsatellite stable colorectal cancer patients. Kaplan-Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with microsatellite stable colorectal cancer. Vertical lines indicate censored observations for comparison of patients without (n = 42) and with MICA-TM A4 allele (n = 12, p = 0.006). The estimated 5-year survival rate was 72% vs 38%, respectively
###end p 49
###begin p 50
###xml 12 20 <span type="species:ncbi:9606">Patients</span>
Survival of Patients with Microsatellite Stable Colorectal Cancer
###end p 50
###begin p 51
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Univariate analysis of tumor-related survival times of patients with microsatellite stable (MIN negative) colorectal cancer and selected MICA-TM (A4, A5, A5,1, A9) and MICB C1_2_A (CA24) alleles in association with indicated clinicopathological parameters (n = 54). Kaplan-Meier analysis and the log rank test were used for comparisons and statistical evaluation
###end p 51
###begin p 52
###xml 237 251 237 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vertical lines</italic>
###xml 356 357 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 433 434 433 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
MICA-TM A4 or A9 haplotype in microsatellite stable colorectal cancer patients. Kaplan-Meier analysis of tumor-related survival times in association with MICA-TM A4 or A9 alleles in patients with microsatellite stable colorectal cancer. Vertical lines indicate censored observations for comparison of patients either positive for MICA-TM A4 or A9 alleles (n = 23) in comparison to patients without MICA-TM A4 and A9 alleles (n = 31, p </= 0.001)
###end p 52
###begin title 53
Conclusions
###end title 53
###begin p 54
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 486 488 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 490 492 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 679 681 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 683 685 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1050 1052 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1275 1277 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1582 1584 1581 1583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 150 155 <span type="species:ncbi:9606">human</span>
###xml 666 671 <span type="species:ncbi:10090">mouse</span>
###xml 1382 1390 <span type="species:ncbi:9606">patients</span>
The NK group 2, member D -NKG2D protein, is an activating cell surface receptor expressed on NK cells and on some T-cell subsets [19, 20]. Ligands of human NKG2D include MICA, MICB, UL-16-binding proteins, and Letal and are expressed on several tumors, especially on epithelium-derived cancer cells [4]. Ligand binding of MICA and MICB to the NKG2D receptor mediates innate antitumor response by stimulation of NK cells and gamma delta T cells and may modulate CD8ass T-cell responses [21, 22]. It was shown that tumor cells expressing high levels of MICA and NKG2D ligands were rejected by NK cells and CD8 alpha/beta T cells and stimulated antitumor activity in a mouse model [23, 24]. Analysis of the structure of the NKG2D-MICA complex by protein expression, crystallization, and crystallography showed the interaction of a NKG2D homodimer with a single MICA monomer either at the alpha 1 or alpha 2 domain forming a relatively stable Interaction, more stable than other T-cell receptor-ligand or other NK cell surface receptor-ligand complexes [25]. Groh et al. have shown an increased tumor antigen cross-presentation and priming of antitumor CD8 and CD4 T-cell responses by loading of dendritic cells with MICA antibodies following coculture with various tumor cells [21]. Recent studies investigating mRNA expression on various benign and malignant tissues and samples from patients with autoimmune diseases have shown a more widely distribution of MICA and MICB expression independent of malignancies or inflammation with the only exception for the central nervous system [26]. So far, it remains unclear whether a different genomic composition of MICA alleles might alter the ligand affinity of MICA alleles to NKG2D receptors and thereby modulate the host antitumor response.
###end p 54
###begin p 55
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
In our study, we observed a significant association of MICA-TM A4 allele with advanced tumor progression and reduced tumor-related survival times. In contrast, patients with the MICA-TM A5 allele had a remarkably low rate of tumor lymph node invasion and less distant metastases. Furthermore, in microsatellite stable tumors, genomic MICA-TM A4 and A9 alleles were related to advanced tumor progression and shorter tumor-related survival, while the MICA-TM A5 allele was again found to have a tumor suppressive effect. These findings first indicate a host imminent predisposition with an altered tumor immune surveillance probably mediated by a differential composition of host MICA-TM alleles in patients with colorectal cancer.
###end p 55
###begin p 56
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
At present, the there is no evidence that the MICA-TM microsatellite polymorphism directly affects NKG2D interaction or shedding of MICA molecules. Interestingly, the MICA-TM A4 and A9 alleles share methionine, M, at amino acid position 129, whereas the A5 alleles always code for valine, V, at this position (IMGT/HLA Database). The MICA-TM alleles 5.1 and 6 do not form a haplogroup with this polymorphic residue and can possess either M or V at amino acid position 129. Steinle et al. [5] have shown that MICA V129 is associated with reduced affinity for NKG2D, whereas M129 confers high NKG2D binding affinity to NKG2D receptors involving the amino acid position M129 might be responsible for the described association with advanced tumor progression and reduced tumor-related survival time. Thus, shedded MICA M129 might more powerfully impair NK and CD8 T-cell responses in vivo and/or downregulate NKG2D expression on effector cells. But, surface MICA M129 might also directly control its pronounced downregulation upon interaction with a strong-affinity MICA protein.
###end p 56
###begin p 57
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 991 995 991 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 1180 1181 1180 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1213 1217 1213 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 501 506 <span type="species:ncbi:9606">human</span>
In other epithelial tumors, Lo et al. have described an association of the MICA-TM A9 allele with gastric cancer and a less schirrous phenotype [27]. The relevance of the NKG2D-ligand immune response in gastric cancer is further supported by Osaki et al. describing a decreased NKG2D expression on CD8+ T cell in patients with gastric cancer [28]. Busche et al. have shown a reduced staining of MICA on the surface of lung cancer samples [29]. In addition, the authors demonstrated in an experimental human lung cancer therapy model that an upregulation of MICA expression in lung cancer cells by adenoviral transfection of expression plasmids was able to reestablish the previously decreased NK cell-mediated antitumor immunity. In thyroid carcinomas, MICA and MICB expression was detected by immunohistochemistry on most tumor samples and on thyroid cancer cell lines with a correlation of their sensitivity to killing by NKG2D-positive NK cells. Transient transfection of mutant BRAF and KRAS oncogenes led to increased MICA and MICB expression in thyroid cancer cells [30]. As shown in our analysis, we only observed a trend for an association of the MICB C1_2_A CA23 allele (p = 0.087) with the detection of KRAS mutations in colorectal cancer samples.
###end p 57
###begin p 58
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 818 826 <span type="species:ncbi:9606">patients</span>
Differential expression of MICA molecules locally present at the surface of tumor cells might additionally regulate local tumor-immune interactions. We therefore cannot rule out that alterations of MICA or MICB at the level of transcription or protein synthesis might result in different levels of MICA and MICB protein expression on the surface of tumor cells. Therefore, the investigation of MICA and MICB alleles at protein expression level on the individual tumor samples will be of further interest. Several studies using immunohistochemistry have shown a reduced expression of MICA at the protein level on tumor cells [27, 29]. It is unclear whether the reduction in MICA protein expression on tumor cells is caused by reduced MICA synthesis or is the result of an increased shedding of MICA molecules in cancer patients.
###end p 58
###begin p 59
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
###xml 620 628 <span type="species:ncbi:9606">patients</span>
The factors involved in shedding of soluble MICA molecules from tumor cells are only poorly understood. It is assumed that metalloproteinases are involved in proteolytic cleavage of soluble MICA molecules from the surface of tumor cells, leading to inactivation of NKG2D mediated antitumor response [31]. Elevated levels of soluble MICA levels were described for patients with gastrointestinal cancer [9]. Interestingly, the authors also report an association of MICA levels with advanced staged of tumor progression especially in patients with gastrointestinal renal, prostate, and breast cancer with highest levels in patients with metastatic disease. It is assumed that the reduction of MICA expression by release and shedding from the cell surface would potentially reduce the immunogenetic signals of tumor cells becoming less detectable for NK and T cells. These findings further support the concept that the NKG2D/ligand system seems to play an important role in the immune surveillance of tumor cells. However, it remains to be determined if any of the described MICA alleles might be related to differential shedding of soluble MICA molecules and thereby influence antitumor immunity and tumor progression.
###end p 59
###begin p 60
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 451 456 <span type="species:ncbi:9606">human</span>
Elevated antibodies against MICA were recently described in tumor patients and in recipients of renal and heart transplants with differential responses to immune therapy or an increased rejection rate associated with a reduced graft survival [32-34]. It is assumed that MICA antibodies are able to opsonize cancer cells for presentation to dendritic cells and induce tumor cell lysis through complement fixation. In addition, genetic modifications of human T cells with chimeric NKG2D receptors might further increase innate antitumor response [35].
###end p 60
###begin p 61
In summary, these findings might indicate a host innate immunogenetic antitumor surveillance associated with advanced colorectal tumor progression and reduced tumor-related survival based on the presence of specific MICA-TM alleles involved in NKG2D-receptor activation.
###end p 61
###begin p 62
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 62
###begin title 63
References
###end title 63
###begin article-title 64
A second lineage of mammalian major histocompatibility complex class I gene
###end article-title 64
###begin article-title 65
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA
###end article-title 65
###begin article-title 66
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
###end article-title 66
###begin article-title 67
Roles of the NKG2D immunoreceptor and its ligand
###end article-title 67
###begin article-title 68
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family
###end article-title 68
###begin article-title 69
###xml 27 32 <span type="species:ncbi:9606">human</span>
Nucleotide sequence of the human MHC class I MICA gene
###end article-title 69
###begin article-title 70
Typing of all known MICA alleles by group-specific PCR and SSOP
###end article-title 70
###begin article-title 71
Mutations designed to destabilize the receptor-bound conformation increase MICA-NKG2D association rate and affinity
###end article-title 71
###begin article-title 72
Soluble MICA in malignant diseases
###end article-title 72
###begin article-title 73
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
###end article-title 73
###begin article-title 74
Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells
###end article-title 74
###begin article-title 75
Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease
###end article-title 75
###begin article-title 76
Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells
###end article-title 76
###begin article-title 77
###xml 53 58 <span type="species:ncbi:9606">human</span>
Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition
###end article-title 77
###begin article-title 78
Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behcet disease
###end article-title 78
###begin article-title 79
A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer
###end article-title 79
###begin article-title 80
Linkage disequilibria between HLA-B, C1_4_1, MICA and MICB
###end article-title 80
###begin article-title 81
MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis
###end article-title 81
###begin article-title 82
Activation of V gamma 9 V delta 2 T cells by NKG2D
###end article-title 82
###begin article-title 83
NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells
###end article-title 83
###begin article-title 84
Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonised cells
###end article-title 84
###begin article-title 85
###xml 46 51 <span type="species:ncbi:9606">human</span>
Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas
###end article-title 85
###begin article-title 86
MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells
###end article-title 86
###begin article-title 87
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human gamma delta T cells: candidates for the development of immunotherapeutic strategies
###end article-title 87
###begin article-title 88
Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA
###end article-title 88
###begin article-title 89
In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer
###end article-title 89
###begin article-title 90
The increase of MICA gene A9 allele associated with gastric cancer and less schirrous change
###end article-title 90
###begin article-title 91
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Decreased NKG2D expression on CD8 + T cell is involved in immune evasion in patients with gastric cancer
###end article-title 91
###begin article-title 92
###xml 55 60 <span type="species:ncbi:9606">human</span>
Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A
###end article-title 92
###begin article-title 93
Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer
###end article-title 93
###begin article-title 94
###xml 41 46 <span type="species:ncbi:9606">human</span>
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding
###end article-title 94
###begin article-title 95
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity
###end article-title 95
###begin article-title 96
Antibodies against MICA antigens and kidney-transplant rejection
###end article-title 96
###begin article-title 97
The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection
###end article-title 97
###begin article-title 98
###xml 69 74 <span type="species:ncbi:9606">human</span>
Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor
###end article-title 98
###begin title 99
Abbreviations
###end title 99
###begin p 100
Union internationale contre le cancer
###end p 100
###begin p 101
Major histocompatibility complex
###end p 101
###begin p 102
Standard deviation
###end p 102
###begin p 103
Hazard ratio
###end p 103
###begin p 104
Confidence interval
###end p 104
###begin p 105
R. Kopp and J. Glas contributed equally to this work and share first authorship.
###end p 105

